Document and Entity Information
Document and Entity Information - shares | 9 Months Ended | |
Sep. 30, 2022 | Oct. 31, 2022 | |
Document information | ||
Document Type | 10-Q | |
Document Quarterly Report | true | |
Document Transition Report | false | |
Document Period End Date | Sep. 30, 2022 | |
Entity File Number | 001-38492 | |
Entity Registrant Name | Kiniksa Pharmaceuticals, Ltd. | |
Entity Incorporation, State or Country Code | D0 | |
Entity Tax Identification Number | 98-1327726 | |
Entity Address, Address Line One | Clarendon House | |
Entity Address, Address Line Two | 2 Church Street | |
Entity Address, City or Town | Hamilton | |
Entity Address, Country | BM | |
Entity Address, Postal Zip Code | HM11 | |
City Area Code | 808 | |
Local Phone Number | 451-3453 | |
Title of 12(b) Security | Class A Common Shares | |
Trading Symbol | KNSA | |
Security Exchange Name | NASDAQ | |
Entity Current Reporting Status | Yes | |
Entity Interactive Data Current | Yes | |
Entity Filer Category | Non-accelerated Filer | |
Entity Small Business | true | |
Entity Emerging Growth Company | false | |
Entity Shell Company | false | |
Current Fiscal Year End Date | --12-31 | |
Document Fiscal Year Focus | 2022 | |
Document Fiscal Period Focus | Q3 | |
Entity Central Index Key | 0001730430 | |
Amendment Flag | false | |
Common Shares | ||
Document information | ||
Entity Common Stock, Shares Outstanding | 69,531,762 | |
Class A common shares | ||
Document information | ||
Entity Common Stock, Shares Outstanding | 34,531,084 | |
Class B common shares | ||
Document information | ||
Entity Common Stock, Shares Outstanding | 1,813,457 | |
Class A1 common shares | ||
Document information | ||
Entity Common Stock, Shares Outstanding | 17,129,603 | |
Class B1 common shares | ||
Document information | ||
Entity Common Stock, Shares Outstanding | 16,057,618 |
CONSOLIDATED BALANCE SHEETS
CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands | Sep. 30, 2022 | Dec. 31, 2021 |
Current assets: | ||
Cash and cash equivalents | $ 175,761 | $ 122,470 |
Short-term investments | 24,963 | 59,731 |
Accounts receivable, net | 11,159 | 3,985 |
Inventory | 14,621 | 3,675 |
Prepaid expenses and other current assets | 15,311 | 6,585 |
Total current assets | 241,815 | 196,446 |
Property and equipment, net | 1,995 | 2,834 |
Operating lease right-of-use assets | 6,173 | 5,550 |
Other long-term assets | 5,627 | 8,720 |
Intangible asset, net | 18,500 | 19,250 |
Deferred tax assets | 185,843 | |
Total assets | 459,953 | 232,800 |
Current liabilities: | ||
Accounts payable | 1,469 | 1,868 |
Accrued expenses | 30,868 | 38,031 |
Deferred revenue | 12,092 | |
Operating lease liabilities | 3,274 | 3,381 |
Other current liabilities | 8,789 | 1,544 |
Total current liabilities | 56,492 | 44,824 |
Non-current liabilities: | ||
Non-current deferred revenue | 14,198 | |
Non-current operating lease liabilities | 3,435 | 2,669 |
Other long-term liabilities | 1,820 | 270 |
Total liabilities | 75,945 | 47,763 |
Commitments and contingencies (Note 14) | ||
Shareholders' equity: | ||
Additional paid-in capital | 880,554 | 860,482 |
Accumulated other comprehensive loss | (70) | (66) |
Accumulated deficit | (496,495) | (675,397) |
Total shareholders' equity | 384,008 | 185,037 |
Total liabilities and shareholders' equity | 459,953 | 232,800 |
Class A common shares | ||
Shareholders' equity: | ||
Common stock value | 9 | 8 |
Class B common shares | ||
Shareholders' equity: | ||
Common stock value | 1 | 1 |
Class A1 common shares | ||
Shareholders' equity: | ||
Common stock value | 5 | 5 |
Class B1 common shares | ||
Shareholders' equity: | ||
Common stock value | $ 4 | $ 4 |
CONSOLIDATED BALANCE SHEETS (Pa
CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares | Sep. 30, 2022 | Dec. 31, 2021 |
Class A common shares | ||
Common stock, par value (in dollars per share) | $ 0.000273235 | $ 0.000273235 |
Common stock, shares issued (in shares) | 34,523,660 | 34,059,725 |
Common stock, shares outstanding (in shares) | 34,523,660 | 34,059,725 |
Class B common shares | ||
Common stock, par value (in dollars per share) | $ 0.000273235 | $ 0.000273235 |
Common stock, shares issued (in shares) | 1,813,457 | 1,813,457 |
Common stock, shares outstanding (in shares) | 1,813,457 | 1,813,457 |
Class A1 common shares | ||
Common stock, par value (in dollars per share) | $ 0.000273235 | $ 0.000273235 |
Common stock, shares issued (in shares) | 17,129,603 | 17,129,603 |
Common stock, shares outstanding (in shares) | 17,129,603 | 17,129,603 |
Class B1 common shares | ||
Common stock, par value (in dollars per share) | $ 0.000273235 | $ 0.000273235 |
Common stock, shares issued (in shares) | 16,057,618 | 16,057,618 |
Common stock, shares outstanding (in shares) | 16,057,618 | 16,057,618 |
CONSOLIDATED STATEMENTS OF OPER
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2022 | Sep. 30, 2021 | Sep. 30, 2022 | Sep. 30, 2021 | |
Revenue: | ||||
Product revenue, net | $ 99,135 | $ 12,095 | $ 158,296 | $ 19,799 |
Costs and operating expenses: | ||||
Research and development | 16,485 | 19,236 | 51,100 | 71,864 |
Selling, general and administrative | 24,677 | 20,759 | 70,736 | 63,207 |
Total operating expenses | 52,722 | 42,762 | 154,570 | 140,304 |
Income (loss) from operations | 46,413 | (30,667) | 3,726 | (120,505) |
Interest income | 322 | 5 | 459 | 20 |
Income (loss) before income taxes | 46,735 | (30,662) | 4,185 | (120,485) |
(Provision) benefit for income taxes | 177,358 | 118 | 174,717 | (1,106) |
Net income (loss) | $ 224,093 | $ (30,544) | $ 178,902 | $ (121,591) |
Net income (loss) per share attributable to common shareholders, basic | $ 3.23 | $ (0.44) | $ 2.58 | $ (1.78) |
Net income (loss) per share attributable to common shareholders, diluted | $ 3.18 | $ (0.44) | $ 2.55 | $ (1.78) |
Weighted average common shares outstanding, basic | 69,445,071 | 68,662,673 | 69,305,755 | 68,444,061 |
Weighted average common shares outstanding, diluted | 70,552,018 | 68,662,673 | 70,286,444 | 68,444,061 |
Comprehensive income (loss): | ||||
Net income (loss) | $ 224,093 | $ (30,544) | $ 178,902 | $ (121,591) |
Other comprehensive income (loss): | ||||
Unrealized gain (loss) on short-term investments and currency translation adjustments, net of tax | 20 | (72) | (4) | (11) |
Total other comprehensive income (loss) | 20 | (72) | (4) | (11) |
Total comprehensive income (loss) | 224,113 | (30,616) | 178,898 | (121,602) |
Product revenue, net | ||||
Revenue: | ||||
Product revenue, net | 33,424 | 12,095 | 82,585 | 19,799 |
Costs and operating expenses: | ||||
Cost of goods sold | 6,937 | $ 2,767 | 16,185 | $ 5,233 |
License and collaboration revenue | ||||
Revenue: | ||||
Product revenue, net | 65,711 | 75,711 | ||
Costs and operating expenses: | ||||
Cost of goods sold | $ 4,623 | $ 16,549 |
CONSOLIDATED STATEMENTS OF SHAR
CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY - USD ($) $ in Thousands | Common Shares | Additional Paid-In Capital | Accumulated Other Comprehensive Income | Accumulated Deficit | Total |
Balance at the beginning of the period at Dec. 31, 2020 | $ 18 | $ 829,424 | $ (34) | $ (517,473) | $ 311,935 |
Balance at the beginning of the period (in shares) at Dec. 31, 2020 | 68,215,022 | ||||
Changes in equity | |||||
Issuance of Class A common shares under incentive award plans | 1,106 | 1,106 | |||
Issuance of Class A common shares under incentive award plans (in shares) | 115,012 | ||||
Share-based compensation expense | 7,126 | 7,126 | |||
Unrealized gain on short-term investments and currency translation adjustments | 13 | 13 | |||
Net income (loss) | (49,484) | (49,484) | |||
Balance at the end of the period at Mar. 31, 2021 | $ 18 | 837,656 | (21) | (566,957) | 270,696 |
Balance at the end of the period (in shares) at Mar. 31, 2021 | 68,330,034 | ||||
Balance at the beginning of the period at Dec. 31, 2020 | $ 18 | 829,424 | (34) | (517,473) | 311,935 |
Balance at the beginning of the period (in shares) at Dec. 31, 2020 | 68,215,022 | ||||
Changes in equity | |||||
Unrealized gain on short-term investments and currency translation adjustments | (11) | ||||
Net income (loss) | (121,591) | ||||
Balance at the end of the period at Sep. 30, 2021 | $ 18 | 853,139 | (45) | (639,064) | 214,048 |
Balance at the end of the period (in shares) at Sep. 30, 2021 | 68,888,435 | ||||
Balance at the beginning of the period at Mar. 31, 2021 | $ 18 | 837,656 | (21) | (566,957) | 270,696 |
Balance at the beginning of the period (in shares) at Mar. 31, 2021 | 68,330,034 | ||||
Changes in equity | |||||
Issuance of Class A common shares under incentive award plans | 887 | 887 | |||
Issuance of Class A common shares under incentive award plans (in shares) | 134,715 | ||||
Share-based compensation expense | 5,717 | 5,717 | |||
Unrealized gain on short-term investments and currency translation adjustments | 48 | 48 | |||
Net income (loss) | (41,563) | (41,563) | |||
Balance at the end of the period at Jun. 30, 2021 | $ 18 | 844,260 | 27 | (608,520) | 235,785 |
Balance at the end of the period (in shares) at Jun. 30, 2021 | 68,464,749 | ||||
Changes in equity | |||||
Issuance of Class A common shares under incentive award plans | 2,680 | 2,680 | |||
Issuance of Class A common shares under incentive award plans (in shares) | 423,686 | ||||
Share-based compensation expense | 6,199 | 6,199 | |||
Unrealized gain on short-term investments and currency translation adjustments | (72) | (72) | |||
Net income (loss) | (30,544) | (30,544) | |||
Balance at the end of the period at Sep. 30, 2021 | $ 18 | 853,139 | (45) | (639,064) | 214,048 |
Balance at the end of the period (in shares) at Sep. 30, 2021 | 68,888,435 | ||||
Balance at the beginning of the period at Dec. 31, 2021 | $ 18 | 860,482 | (66) | (675,397) | 185,037 |
Balance at the beginning of the period (in shares) at Dec. 31, 2021 | 69,060,403 | ||||
Changes in equity | |||||
Issuance of Class A common shares under incentive award plans | $ 1 | 422 | 423 | ||
Issuance of Class A common shares under incentive award plans (in shares) | 210,720 | ||||
Share-based compensation expense | 6,031 | 6,031 | |||
Unrealized gain on short-term investments and currency translation adjustments | (37) | (37) | |||
Net income (loss) | (25,210) | (25,210) | |||
Balance at the end of the period at Mar. 31, 2022 | $ 19 | 866,935 | (103) | (700,607) | 166,244 |
Balance at the end of the period (in shares) at Mar. 31, 2022 | 69,271,123 | ||||
Balance at the beginning of the period at Dec. 31, 2021 | $ 18 | 860,482 | (66) | (675,397) | 185,037 |
Balance at the beginning of the period (in shares) at Dec. 31, 2021 | 69,060,403 | ||||
Changes in equity | |||||
Unrealized gain on short-term investments and currency translation adjustments | (4) | ||||
Net income (loss) | 178,902 | ||||
Balance at the end of the period at Sep. 30, 2022 | $ 19 | 880,554 | (70) | (496,495) | 384,008 |
Balance at the end of the period (in shares) at Sep. 30, 2022 | 69,524,338 | ||||
Balance at the beginning of the period at Mar. 31, 2022 | $ 19 | 866,935 | (103) | (700,607) | 166,244 |
Balance at the beginning of the period (in shares) at Mar. 31, 2022 | 69,271,123 | ||||
Changes in equity | |||||
Issuance of Class A common shares under incentive award plans | 542 | 542 | |||
Issuance of Class A common shares under incentive award plans (in shares) | 155,644 | ||||
Share-based compensation expense | 6,676 | 6,676 | |||
Unrealized gain on short-term investments and currency translation adjustments | 13 | 13 | |||
Net income (loss) | (19,981) | (19,981) | |||
Balance at the end of the period at Jun. 30, 2022 | $ 19 | 874,153 | (90) | (720,588) | 153,494 |
Balance at the end of the period (in shares) at Jun. 30, 2022 | 69,426,767 | ||||
Changes in equity | |||||
Issuance of Class A common shares under incentive award plans | 360 | 360 | |||
Issuance of Class A common shares under incentive award plans (in shares) | 97,571 | ||||
Share-based compensation expense | 6,041 | 6,041 | |||
Unrealized gain on short-term investments and currency translation adjustments | 20 | 20 | |||
Net income (loss) | 224,093 | 224,093 | |||
Balance at the end of the period at Sep. 30, 2022 | $ 19 | $ 880,554 | $ (70) | $ (496,495) | $ 384,008 |
Balance at the end of the period (in shares) at Sep. 30, 2022 | 69,524,338 |
CONSOLIDATED STATEMENTS OF CASH
CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands | 9 Months Ended | |
Sep. 30, 2022 | Sep. 30, 2021 | |
Cash flows from operating activities: | ||
Net income (loss) | $ 178,902 | $ (121,591) |
Adjustments to reconcile net income (loss) to net cash used in operating activities: | ||
Depreciation and amortization | 1,800 | 1,687 |
Share-based compensation expense | 18,748 | 19,042 |
Non-cash lease expense | 2,253 | 1,895 |
Amortization of premiums and accretion of discounts on short-term investments | 121 | 617 |
Loss on disposal of property and equipment | 23 | |
Deferred income taxes | (185,843) | |
Changes in operating assets and liabilities: | ||
Prepaid expenses and other current assets | (8,726) | 1,034 |
Accounts receivable, net | (7,174) | (3,224) |
Inventory | (10,946) | (5,606) |
Other long-term assets | 2,919 | (1,059) |
Accounts payable | (399) | 1,116 |
Accrued expenses and other current liabilities | 82 | 295 |
Operating lease liabilities | (2,217) | (1,700) |
Deferred revenue | 26,290 | |
Other long-term liabilities | 1,550 | 80 |
Net cash provided (used) in operating activities | 17,383 | (107,414) |
Cash flows from investing activities: | ||
Proceeds from sale of property and equipment | 81 | |
Purchases of property and equipment | (137) | (164) |
Purchases of short-term investments | (73,062) | (97,460) |
Proceeds from the maturities of short-term investments | 107,700 | 296,300 |
Intangible asset acquired | (20,000) | |
Net cash provided by investing activities | 34,582 | 178,676 |
Cash flows from financing activities: | ||
Proceeds from issuance of Class A common shares under incentive award plans and employee share purchase plans | 2,127 | 4,673 |
Payments in connection with Common Stock tendered for employee tax obligations | (801) | |
Net cash provided by financing activities | 1,326 | 4,673 |
Net increase in cash, cash equivalents and restricted cash | 53,291 | 75,935 |
Cash, cash equivalents and restricted cash at beginning of period | 122,470 | 114,248 |
Cash, cash equivalents and restricted cash at end of period | 175,761 | 190,183 |
Supplemental information: | ||
Cash paid for income taxes | 4,608 | 859 |
Supplemental disclosure of non-cash investing and financing activities: | ||
Right-of-use asset obtained in exchange for operating lease obligation | $ 2,876 | $ 1,462 |
Nature of the Business and Basi
Nature of the Business and Basis of Presentation | 9 Months Ended |
Sep. 30, 2022 | |
Nature of the Business and Basis of Presentation | |
Nature of the Business and Basis of Presentation | 1. Nature of the Business and Basis of Presentation Kiniksa Pharmaceuticals, Ltd. (the “Company”) is a biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. The Company’s portfolio of assets is based on strong biologic rationale or validated mechanisms, target underserved conditions and offer the potential for differentiation. The Company is subject to risks and uncertainties common to early, commercial stage companies in the biopharmaceutical industry and global health, societal, economic and market conditions, including the Company’s dependence on third parties, including contract research organizations and contract manufacturing organizations, the Company’s limited experience obtaining regulatory approvals, the potential failure of the Company to successfully complete research and development of its current or future product candidates, the potential inability of the Company to adequately protect its technology, potential competition, the uncertainty that any current or future product candidates will obtain necessary government regulatory approval, that ARCALYST will continue to be commercially viable, whether any of the Company’s current or future product candidates, if approved, will be commercially viable, adverse impact from the coronavirus disease 2019 (“COVID-19”) pandemic and global and political turmoil, including the ongoing war in Ukraine. Such risks and uncertainties, especially those risks and uncertainties arising from the ongoing COVID-19 pandemic, may be subject to substantial and uncertain changes, which may cause significant disruption to the Company’s business and operations, preclinical studies and clinical trials, the business and operations of the third parties with whom the Company conducts business and the national and global economies, all of which may have material impacts on the Company’s business, financial condition and results of operations. Principles of Consolidation The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) and include the accounts of the Company and its wholly owned subsidiaries, Kiniksa Pharmaceuticals Corp. (“Kiniksa US”), Primatope Therapeutics, Inc. (“Primatope”) and Kiniksa Pharmaceuticals (UK), Ltd. (“Kiniksa UK”) as well as the subsidiaries of Kiniksa UK, Kiniksa Pharmaceuticals (Germany) GmbH (“Kiniksa Germany”), Kiniksa Pharmaceuticals (France) SARL (“Kiniksa France”), and Kiniksa Pharmaceuticals GmbH (“Kiniksa Switzerland”), after elimination of all significant intercompany accounts and transactions. Use of Estimates The preparation of the Company’s consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting period. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, the recognition of revenue, the capitalization of inventory, the accrual for research and development expenses, the valuation of share-based awards and the realizability of deferred tax assets. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ from those estimates. Unaudited Interim Consolidated Financial Information The accompanying unaudited consolidated financial statements have been prepared in accordance with GAAP for interim financial information. The accompanying unaudited consolidated financial statements do not include all of the information and footnotes required by GAAP for complete consolidated financial statements. The information included in this quarterly report on Form 10-Q should be read in conjunction with the Company’s audited consolidated financial statements and the accompanying notes included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021 (the “2021 Form 10-K”). The Company’s accounting policies are described in the Notes to Consolidated Financial Statements in the Company’s 2021 Form 10-K and updated, as necessary, in this report. The accompanying year-end consolidated balance sheet was derived from audited financial statements but does not include all disclosures required by GAAP. The unaudited interim consolidated financial statements have been prepared on the same basis as the audited annual consolidated financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary for the fair statement of the Company’s financial position as of September 30, 2022 and the results of its operations for the three and nine months ended September 30, 2022 and 2021, the changes in its shareholders’ equity for the three and nine months ended September 30, 2022 and 2021 and its cash flows for the nine months ended September 30, 2022 and 2021. The results for the three and nine months ended September 30, 2022 are not necessarily indicative of results to be expected for the year ending December 31, 2022, any other interim periods or any future year or period. Liquidity The Company has evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date the consolidated financial statements are issued. As of September 30, 2022, the Company had an accumulated deficit of $496,495. During the nine months ended September 30, 2022, the Company reported net income of $178,902 and provided $17,383 cash in operating activities. As of September 30, 2022, the Company had cash, cash equivalents and short-term investments of $200,724. Based on its current operating plan, the Company expects that its cash, cash equivalents and short-term investments will be sufficient to fund its operations and capital expenditure requirements for at least twelve months from the issuance date of these consolidated financial statements. The future viability of the Company beyond that point is dependent on its ability to fund its operations through sales of ARCALYST and/or raise additional capital, as needed. If the Company is unable to grow sales of ARCALYST in future periods, the Company would need to seek additional financing through public or private securities offerings, debt financings, government funding or grants, or other sources, which may include licensing, collaborations or other strategic transactions or arrangements. Although the Company has been successful in raising capital in the past, there is no assurance that it will be successful in obtaining such additional financing on terms acceptable to the Company, if at all. If the Company is unable to obtain funding, the Company could be forced to delay, reduce or eliminate some or all of its commercialization efforts, research and development programs for product candidates or product portfolio expansion, which could adversely affect its business prospects, or the Company may be unable to continue operations. |
Summary of Significant Accounti
Summary of Significant Accounting Policies | 9 Months Ended |
Sep. 30, 2022 | |
Summary of Significant Accounting Policies | |
Summary of Significant Accounting Policies | 2. Summary of Significant Accounting Policies Revenue Recognition ASC Topic 606, Revenue from Contracts with Customers (“ASC 606”) outlines a five-step process for recognizing revenue from contracts with customers: (i) identify the contract with the customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, (iv) allocate the transaction price to the separate performance obligations in the contract, and (v) recognize revenue associated with the performance obligations as they are satisfied. The Company only applies the five-step model to contracts when it is probable that the Company will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. Once a contract is determined to be within the scope of ASC 606, the Company determines the performance obligations that are distinct. The Company recognizes as revenues the amount of the transaction price that is allocated to each respective performance obligation when the performance obligation is satisfied. Generally, the Company’s performance obligations are transferred to customers at a point in time, typically upon delivery of the product to the customer. ASC 606 requires entities to record a contract asset when a performance obligation has been satisfied or partially satisfied, but the amount of consideration has not yet been received because the receipt of the consideration is conditioned on something other than the passage of time. ASC 606 also requires an entity to present a revenue contract as a contract liability in instances when a customer pays consideration, or an entity has a right to an amount of consideration that is unconditional (e.g., receivable), before the entity transfers a good or service to the customer. Collaboration Revenue The Company analyzes its collaboration arrangements to assess whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards dependent on the commercial success of such activities and therefore within the scope of ASC Topic 808, Collaborative Arrangements (“Topic 808”). This assessment is performed throughout the life of the arrangement based on changes in the responsibilities of all parties in the arrangement. For collaboration arrangements within the scope of Topic 808 that contain multiple elements, the Company first determines which elements of the collaboration are deemed to be within the scope of Topic 808 and which elements of the collaboration are more reflective of a vendor-customer relationship and therefore within the scope of Topic 606. For elements of collaboration arrangements that are accounted for pursuant to ASC 606, we identify the performance obligations and allocate the total consideration we expect to receive on a relative standalone selling price basis to each performance obligation. Variable consideration such as performance-based milestones will be included in the total consideration if we expect to receive such consideration and if it is probable that the inclusion of the variable consideration will not result in a significant reversal in the cumulative amount of revenue recognized under the arrangement. Our estimate of the total consideration we expect to receive under each collaboration arrangement is updated for each reporting period, and any adjustments to revenue are recorded on a cumulative catch-up basis. We exclude sales-based royalty and milestone payments from the total consideration we expect to receive until the underlying sales occur because the license to our intellectual property is deemed to be the predominant item to which the royalties or milestones relate as it is the primary driver of value in our collaboration arrangements. Key assumptions to determine the standalone selling price may include forecasted revenues, development timelines, reimbursement rates for personnel costs, discount rates and probabilities of technical and regulatory success. We recognize revenue associated with each performance obligation as the control over the promised goods or services transfer to our collaboration partner which occurs either at a point in time or over time. If control transfers over time, revenue is recognized by using a method of measuring progress that best depicts the transfer of goods or services. We evaluate the measure of progress and related inputs each reporting period and any resulting adjustments to revenue are recorded on a cumulative catch-up basis. Consideration received that does not meet the requirements to satisfy ASC 808 or ASC 606 revenue recognition criteria is recorded as deferred revenue in the accompanying consolidated balance sheets, classified as either short-term (less than 12 months) or long-term (more than 12 months) deferred revenue based on our best estimate of when such revenue will be recognized. There have been no other material changes to the significant accounting policies previously disclosed in the Company’s 2021 Form 10-K. Recently Adopted Accounting Pronouncements |
Fair Value of Financial Assets
Fair Value of Financial Assets and Liabilities | 9 Months Ended |
Sep. 30, 2022 | |
Fair Value of Financial Assets and Liabilities | |
Fair Value of Financial Assets and Liabilities | 3. Fair Value of Financial Assets and Liabilities Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable: ● Level 1—Quoted prices in active markets for identical assets or liabilities. ● Level 2—Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data. ● Level 3—Unobservable inputs that are supported by little or no market activity that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques. The following tables present information about the Company’s financial instruments measured at fair value on a recurring basis and indicate the level of the fair value hierarchy used to determine such fair values: Fair Value Measurements as of September 30, 2022 Using: Level 1 Level 2 Level 3 Total Assets: Cash equivalents — money market funds $ 39,533 $ — $ — $ 39,533 Short-term investments — U.S. Treasury notes — 24,963 — 24,963 $ 39,533 $ 24,963 $ — $ 64,496 Fair Value Measurements as of December 31, 2021 Using: Level 1 Level 2 Level 3 Total Assets: Cash equivalents — money market funds $ 94,324 $ — $ — $ 94,324 Short-term investments — U.S. Treasury notes — 59,731 — 59,731 $ 94,324 $ 59,731 $ — $ 154,055 During the nine months ended September 30, 2022 and the year ended December 31, 2021 there were no transfers between Level 1, Level 2 and Level 3. The money market funds were valued using quoted prices in active markets, which represent a Level 1 measurement in the fair value hierarchy. The Company’s cash equivalents and short-term investments as of September 30, 2022 and December 31, 2021 included U.S. Treasury notes, which are not traded on a daily basis and, therefore, represent a Level 2 measurement in the fair value hierarchy at each period end. Gross Gross Amortized Unrealized Unrealized Credit Fair Cost Gains Losses Losses Value September 30, 2022 Short-term investments — U.S. Treasury notes $ 24,986 $ — $ (23) $ — $ 24,963 $ 24,986 $ — $ (23) $ — $ 24,963 Gross Gross Amortized Unrealized Unrealized Credit Fair Cost Gains Losses Losses Value December 31, 2021 Short-term investments — U.S. Treasury notes $ 59,745 $ 1 $ (15) $ — $ 59,731 $ 59,745 $ 1 $ (15) $ — $ 59,731 As of September 30, 2022, the Company held 6 securities that were in an unrealized loss position. The aggregate fair value of securities held by the Company in an unrealized loss position was $22,466 at September 30, 2022. As of December 31, 2021, the Company held 11 securities that were in an unrealized loss position. The aggregate fair value of securities held by the Company in an unrealized loss position was $49,739 at December 31, 2021. As of September 30, 2022 and December 31, 2021, these securities were held by the Company in an unrealized loss position for less than 12 months. The Company determined that there was no material change in the credit risk of these securities. As a result, the Company determined it did not hold any investments with an other-than-temporary impairment as of September 30, 2022 and December 31, 2021. |
Product Revenue, Net
Product Revenue, Net | 9 Months Ended |
Sep. 30, 2022 | |
Product Revenue, Net | |
Product Revenue, Net | 4. Product Revenue, Net ARCALYST Following the approval by the U.S. Food and Drug Administration (“FDA”) of ARCALYST on March 18, 2021, the Company began generating product revenue from sales of ARCALYST in April 2021. Three Months Ended Nine Months Ended September 30, September 30, 2022 2021 2022 2021 Product revenue, net $ 33,424 $ 12,095 $ 82,585 $ 19,799 The following table summarizes balances and activity in each of the product revenue allowance and reserve categories for the nine months ended September 30, 2022: Contractual Government Adjustments Rebates Returns Total Balance at December 31, 2021 $ 515 $ 719 $ 101 $ 1,335 Current provisions relating to sales in the current year 4,993 3,011 227 8,231 Payments/returns relating to sales in the current year (3,797) (1,659) — (5,456) Payments/returns relating to sales in the prior years (295) (535) — (830) Balance at September 30, 2022 $ 1,416 $ 1,536 $ 328 $ 3,280 Total revenue-related reserves as of September 30, 2022 and December 31, 2021, included in our consolidated balance sheets, are summarized as follows: September 30, December 31, 2022 2021 Reduction of accounts receivable $ (157) $ (50) Components of other current liabilities 3,437 1385 Total revenue-related reserves $ 3,280 $ 1,335 |
Inventory
Inventory | 9 Months Ended |
Sep. 30, 2022 | |
Inventory | |
Inventory | 5. Inventory Inventory consisted of the following: September 30, December 31, 2022 2021 Raw materials $ — $ — Work-in-process — — Finished Goods 14,621 3,675 $ 14,621 $ 3,675 |
Property and Equipment, Net
Property and Equipment, Net | 9 Months Ended |
Sep. 30, 2022 | |
Property and Equipment, Net | |
Property and Equipment, Net | 6. Property and Equipment, Net Property and equipment, net consisted of the following: September 30, December 31, 2022 2021 Furniture, fixtures and vehicles $ 224 $ 62 Computer hardware and software 345 341 Leasehold improvements 3,931 3,931 Lab equipment 4,068 4,249 Construction in progress 32 166 Total property and equipment 8,600 8,749 Less: Accumulated depreciation (6,605) (5,915) Total property and equipment, net $ 1,995 $ 2,834 Depreciation expense was $177 and $373 during the three months ended September 30, 2022 and 2021, respectively, and $885 and $1,079 during the nine months ended September 30, 2022 and 2021, respectively. |
Intangible Assets
Intangible Assets | 9 Months Ended |
Sep. 30, 2022 | |
Intangible Assets | |
Intangible Assets | 7. Intangible Assets Intangible assets, net of accumulated amortization, impairment charges and adjustments as of September 30, 2022 and December 31, 2021 are summarized in the following table. As of September 30, 2022 As of December 31, 2021 Estimated Accumulated Accumulated life Cost Amortization Net Cost Amortization Net Regulatory milestone 20 years $ 20,000 $ 1,500 $ 18,500 $ 20,000 $ 750 $ 19,250 $ 20,000 $ 1,500 $ 18,500 $ 20,000 $ 750 $ 19,250 |
Accrued Expenses
Accrued Expenses | 9 Months Ended |
Sep. 30, 2022 | |
Accrued Expenses | |
Accrued Expenses | 8. Accrued Expenses Accrued expenses consisted of the following: September 30, December 31, 2022 2021 Accrued research and development expenses $ 13,559 $ 24,977 Accrued employee compensation and benefits 8,316 8,916 Accrued collaboration expenses 4,660 835 Accrued legal, commercial and professional fees 3,754 2,933 Other 579 370 $ 30,868 $ 38,031 |
Share-Based Compensation
Share-Based Compensation | 9 Months Ended |
Sep. 30, 2022 | |
Share-Based Compensation | |
Share-Based Compensation | 9. Share-Based Compensation The Company maintains several equity compensation plans, including the 2018 Incentive Award Plan (the “2018 Plan”), 2018 Employee Share Purchase Plan (the “2018 ESPP”), and Rilonacept Long-Term Incentive Plan (“RLTIP”) which was approved under the 2018 Plan. Upon the effectiveness of the 2018 Plan, the Company ceased granting awards under its 2015 Equity Incentive Plan (as amended, the “2015 Plan” and together with the 2018 Plan, the “Plans”). 2015 Plan As of September 30, 2022, there were 2,029,355 Class A common shares subject to outstanding awards under the 2015 Plan and reserved for issuance thereunder pursuant to such awards. 2018 Plan In May 2018, the Company’s board of directors and shareholders approved the 2018 Plan, which became effective on May 23, 2018. The 2018 Plan provides for the grant of incentive share options, nonqualified share options, share appreciation rights, restricted shares, dividend equivalents, restricted share units (“RSUs”) and other share- or cash- based awards. Pursuant to the 2018 Plan’s evergreen provision, the number of shares available for future issuance under the 2018 Plan, as of January 1, 2022, increased by 2,762,416 Class A common shares. As of September 30, 2022, 4,117,546 shares remained available for future grant under the 2018 Plan. 2018 ESPP In December 2021, pursuant to the 2018 ESPP’s evergreen provision, the Company’s board of directors approved an increase in the number of shares available for future issuance under the 2018 ESPP, as of January 1, 2022, of 90,000 Class A common shares. As of September 30, 2022, 604,290 Class A common shares were available for future issuance under the 2018 ESPP. Options Share option activity under the Plans is summarized as follows: Weighted Number of Average Shares Exercise Price Outstanding as of December 31, 2021 9,226,846 $ 14.14 Granted 2,792,460 $ 11.22 Exercised (226,230) $ 5.81 Forfeited (1,468,620) $ 15.59 Outstanding as of September 30, 2022 10,324,456 $ 13.32 Share options exercisable as of September 30, 2022 5,525,898 $ 13.52 Share options unvested as of September 30, 2022 4,798,558 $ 13.10 As of September 30, 2022, total unrecognized compensation expense related to the unvested share option awards was $40,360 which is expected to be recognized over a weighted average remaining period of 2.73 years. Restricted Share Units Beginning in March 2021, the Company began granting RSUs with service conditions (“Time-Based RSUs”) to eligible employees as part of its equity incentive compensation. The Time-Based RSUs vest 25% on each of the first, second, third and fourth anniversaries of the date of grant, subject to continued employment through such dates. During the years ended December 31, 2020 and 2019, the Company granted the first RSU awards (“First RLTIP RSU Awards”) as part of the RLTIP to eligible employees. During the year ended December 31, 2021, the FDA Milestone (as defined in RLTIP) was achieved (the date of such achievement, the “Achievement Date”) and (1) the number of Class A common shares issuable under the First RLTIP RSU Awards were determined in accordance with the RLTIP and vested in one installment on the first anniversary of the Achievement Date, subject to continued employment through such date, and (2) the Company granted a second set of RSU awards to eligible employees on the Achievement Date with respect to a number of shares determined in accordance with the RLTIP, which will vest on the second anniversary of the Achievement Date, subject to continued employment through such date. During the three months ended September 30, 2022 and 2021, the Company recognized compensation expense of $1,146 and $838, respectively, related to RSUs including those granted in connection with the RLTIP. During the nine months ended September 30, 2022 and 2021, the Company recognized compensation expense of $2,697 and $2,868, respectively, related to RSUs including those granted in connection with the RLTIP. The following table summarizes RSU activity, including the RSUs outstanding under the RLTIP for the nine months ended September 30, 2022: Weighted Average Number of Grant Date Shares Fair Value Unvested RSUs as of December 31, 2021 885,021 $ 15.72 Granted 1,318,583 $ 10.71 Vested (229,151) $ 15.79 Forfeited (320,710) $ 14.08 Unvested RSUs as of September 30, 2022 1,653,743 $ 13.17 As of September 30, 2022, total unrecognized compensation cost related to the RSU awards was $17,821 which is expected to be recognized over a weighted average remaining period of 3.38 years. Share-Based Compensation Share-based compensation expense was classified in the consolidated statements of operations and comprehensive loss as follows: Three Months Ended Nine Months Ended September 30, September 30, 2022 2021 2022 2021 Cost of goods sold $ 164 $ 62 $ 456 $ 101 Research and development expenses 1,532 1,912 5,116 6,469 Selling, general and administrative expenses 4,345 4,225 13,176 12,472 $ 6,041 $ 6,199 $ 18,748 $ 19,042 |
Out-Licensing Agreements
Out-Licensing Agreements | 9 Months Ended |
Sep. 30, 2022 | |
Out-licensing Agreements | |
Out-licensing Agreements | 10. Genentech License Agreement On August 2, 2022, the Company entered into a license agreement (the “Genentech License Agreement”) with Genentech, Inc. and F. Hoffmann-La Roche Ltd (collectively, “Genentech”), pursuant to which the Company granted Genentech exclusive worldwide rights to develop, manufacture and commercialize vixarelimab and related antibodies (each, a “Genentech Licensed Product”). The Genentech License Agreement became effective on September 12, 2022 (the “Genentech Effective Date”) following termination of the statutory waiting period under the Hart-Scott Rodino Act. Under the Genentech License Agreement, the Company received an upfront payment of $80,000 for the license and is eligible to receive a near-term cash payment of $20,000 for delivery of certain materials to Genentech. In addition, the Company will be eligible to receive up to approximately $600,000 in contingent payments, including specified development, regulatory and sales-based milestones, before fulfilling the Company’s upstream financial obligations. The Company will also be eligible to receive tiered percentage royalties on a Genentech Licensed Product-by-Genentech Licensed Product basis ranging from low-double digits to mid-teens on annual net sales of each Genentech Licensed Product, subject to certain customary reductions, with an aggregate minimum floor, before fulfilling the Company’s upstream financial obligations. Royalties will be payable on a Genentech Licensed Product-by-Genentech Licensed Product and country-by-country basis until the latest to occur of the expiration of certain patents that cover a Genentech Licensed Product, the expiration of regulatory exclusivity for such Genentech Licensed Product, or the tenth anniversary of first commercial sale of such Genentech Licensed Product in such country. Pursuant and subject to the terms of the Genentech License Agreement, Genentech has the exclusive worldwide right to conduct development and commercialization activities for Genentech Licensed Products at its sole cost. Notwithstanding the foregoing, the Company is responsible, at its sole cost, for continuing to conduct and finalize its Phase 2b clinical trial assessing the efficacy, safety and tolerability of vixarelimab in reducing pruritis in prurigo nodularis. Both the Company and Genentech participate in a joint transition committee, which coordinates and oversees the technology and inventory transition activities relating to the development of the Genentech Licensed Products and the Company’s conduct and finalization of its Phase 2b clinical trial. The Company will provide to Genentech an initial drug supply and a drug product resupply and Genentech will be obligated to pay $20,000 to the Company after delivery of the last of such supply; provided Agreement at cost plus a markup. Under the Genentech License Agreement, Genentech has the right to assume manufacturing responsibilities for Genentech Licensed Products. Absent early termination, the Genentech License Agreement will continue until there are no more royalty or other payment obligations owed to the Company. Genentech has the right to terminate the Genentech License Agreement at its discretion with prior written notice and either party may terminate the Genentech License Agreement in the event of an uncured material breach of the other party or in the case of insolvency of the other party. In addition, the Genentech License Agreement will terminate upon termination of the Biogen Agreement (as defined below). The Company concluded that Genentech is a customer in this license agreement, and as such, the Genentech License Agreement falls within the scope of the revenue recognition guidance in ASC 606. Accounting for Genentech License Agreement As of the Genentech Effective Date, the Company identified the following material promises in the Genentech License Agreement: (i) the delivery of the exclusive license for vixarelimab; (ii) an initial drug supply delivery; (iii) a drug product resupply delivery; and (iv) completion of the Phase 2b clinical trial for vixarelimab. The Company also evaluated whether certain options outlined within the Genentech License Agreement represented material rights that would give rise to a performance obligation, including the option to purchase additional drug substance, and concluded that none of the options convey a material right to Genentech and therefore are not considered separate performance obligations within the Genentech License Agreement. The Company assessed the above promises and determined that the exclusive license for vixarelimab is reflective of a vendor-customer relationship and therefore represents a performance obligation. The exclusive license for vixarelimab is considered functional intellectual property and distinct from other promises under the Genentech License Agreement as Genentech can benefit from the license on its own or together with other readily available resources and the license is separately identifiable from the other promises. The initial drug supply and drug product resupply are considered distinct from the exclusive license for vixarelimab as Genentech can benefit from such supply together with the license transferred by the Company at the inception of the Genentech License Agreement. The completion of the Phase 2b clinical trial is considered distinct from the exclusive license for vixarelimab as Genentech can benefit from the data generated by such trial together with such license. Therefore, each represents a separate performance obligation within a contract with a customer at contract inception. The Company determined the transaction price at the inception of the Genentech License Agreement which consists of the $80,000 upfront payment. The Company determined that any variable consideration, including the $20,000 related to the delivery of the initial drug supply and drug product resupply and future development and regulatory milestones, are deemed fully constrained and therefore excluded from the transaction price due to the high degree of uncertainty and risk associated with these potential payments, as the Company also determined that it could not assert that it was not probable that a significant reversal in the amount of cumulative revenue recognized would occur. The Company also determined that royalties and sales milestones relate solely to the license of intellectual property. Revenue related to these royalties and sales milestones will only be recognized when the associated sales occur, and relevant thresholds are met, under the sales or usage-based royalty exception of Topic 606. As noted above, the Company identified four performance obligations in the Genentech License Agreement: (i) the delivery of the exclusive license for vixarelimab; (ii) an initial drug supply delivery; (iii) a drug product resupply delivery; and (iv) completion of the Phase 2b clinical trial for vixarelimab. The selling price of each performance obligation in the Genentech License Agreement was determined based on the Company’s standalone selling price (“SSP”) with the objective of determining the price at which it would sell such an item if it were to be sold regularly on a standalone basis. The Company allocated the transaction price to the exclusive license, initial drug supply delivery, drug product resupply delivery and completion of the Phase 2b clinical trial for vixarelimab. The Company recognizes revenue for the license performance obligations at a point in time, that is upon transfer of the license to Genentech. As control of the license was transferred on the Genentech Effective Date and Genentech could begin to use and benefit from the license, the Company recognized $65,711 of collaboration revenue during the three and nine months ended September 30, 2022 under the Genentech License Agreement. The Company will recognize revenue for deliveries of certain drug supply to Genentech at a point in time upon delivery. The Company will recognize revenue for the completion of the Phase 2b clinical trial for vixarelimab over time using the cost-to-cost input method, which it believes best depicts the transfer of control to the customer. Under the cost-to-cost input method, the extent of progress towards completion is measured based on the ratio of actual costs incurred to the total estimated costs expected upon satisfying the identified performance obligation. Under this method, revenue is recorded as a percentage of the allocated transaction price based on the progress of completion. The calculation of the total estimated costs to fulfill the performance obligation includes costs associated with employees, development, manufacturing, and out-of-pocket costs expected to be paid to third parties. Huadong Collaboration Agreements On February 21, 2022 (the “Effective Date”), the Company entered into two collaboration and license agreements (each, a “Collaboration Agreement” and together, the “Collaboration Agreements”) with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. (“Huadong”), pursuant to which the Company granted Huadong exclusive rights to develop and commercialize rilonacept and develop, manufacture and commercialize mavrilimumab (each, a “Licensed Product” and together, the “Licensed Products”) in the following countries: People’s Republic of China, Hong Kong SAR, Macao SAR, Taiwan Region, South Korea, Indonesia, Singapore, The Philippines, Thailand, Australia, Bangladesh, Bhutan, Brunei, Burma, Cambodia, India, Laos, Malaysia, Maldives, Mongolia, Nepal, New Zealand, Sri Lanka, and Vietnam (collectively, the “Territory”). Under the Collaboration Agreements, the Company received a total upfront cash payment of $22,000, which includes $12,000 for the Territory license of rilonacept and $10,000 for the Territory license of mavrilimumab. The Company will be eligible to receive up to approximately $70,000 in payments for rilonacept, and up to approximately $576,000 in payments for mavrilimumab, including specified development, regulatory and sales-based milestones. Huadong will also be obligated to pay the Company tiered percentage royalties on a Licensed Product-by-Licensed Product basis ranging from the low-teens to low-twenties on annual net sales of each Licensed Product in the Territory, subject to certain reductions tied to rilonacept manufacturing costs and certain other customary reductions, with an aggregate minimum floor. Royalties will be payable on a Licensed Product-by-Licensed Product and country-by-country or region-by-region basis until the later of (i) 12 years after the first commercial sale of the applicable Licensed Product in such country or region in the Territory, (ii) the date of expiration of the last valid patent claim of the Company’s patent rights or any joint collaboration patent rights that covers the applicable Licensed Product in such country or region in the Territory, and (iii) the expiration of the last regulatory exclusivity for the applicable Licensed Product in such country or region in the Territory. Pursuant and subject to the terms of the Collaboration Agreements, Huadong has the exclusive right to conduct Territory-specific development activities for the Licensed Products in the Territory, the first right to support global development of the Licensed Products by serving as the sponsor of the global clinical trials conducted in the Territory and the exclusive right to commercialize the Licensed Products in the Territory. Huadong will be responsible for all costs of development activities and commercialization in the Territory. Both the Company and Huadong participate in a Joint Steering Committee (“JSC”), which coordinates and oversees the exploitation of the Licensed Products in the Territory. The Company will supply certain materials to support development and commercialization activities for both mavrilimumab and rilonacept. Under the Collaboration Agreement for mavrilimumab, Huadong has the right to assume manufacturing responsibilities for materials in the Territory. Under the Collaboration Agreement for rilonacept, Huadong does not have rights to perform manufacturing activities in the Territory. Absent early termination, each Collaboration Agreement will continue on a country-by-country or region-by-region basis until there are no more royalty payments owed to the Company in such country or region for the applicable Licensed Product. Huadong has the right to terminate each Collaboration Agreement at its discretion upon 12 months’ notice and either party may terminate the applicable Collaboration Agreement in the event of an uncured material breach of the other party or in the case of insolvency of the other party. In addition, the Company may terminate the applicable Collaboration Agreement if Huadong or its affiliates or sublicensees challenges the scope, validity, or enforceability of the Company’s patent rights being licensed to Huadong. If Huadong and its affiliates do not conduct any material development or commercialization activities with respect to a Licensed Product in the People’s Republic of China for a continuous period of longer than six months, then, subject to certain exceptions, the Company may terminate the Collaboration Agreement applicable to such Licensed Product with 60 days’ prior written notice. In addition, Huadong’s rights under each Collaboration Agreement in certain regions within the Territory may be subject to termination upon failure by Huadong to perform certain clinical, development or commercialization activities, as applicable, with respect to the applicable Licensed Product in such regions. The Company concluded that Huadong is a customer in these Collaboration Agreements, and as such, each Collaboration Agreement falls within the scope of the revenue recognition guidance in ASC 606. The Company concluded that the Collaboration Agreements should not be combined and treated as a single arrangement for accounting purposes as the Collaboration Agreements were negotiated separately with separate and distinct commercial objectives, the amount of consideration in one Collaboration Agreement is not dependent on the price or performance of the other Collaboration Agreement, and the goods and services promised in the Collaboration Agreements are not a single performance obligation. Accounting for Mavrilimumab Collaboration Agreement As of the Effective Date, the Company identified the following material promises in the mavrilimumab Collaboration Agreement: delivery of (i) exclusive license for mavrilimumab in the Territory and (ii) clinical manufacturing supply of certain materials for mavrilimumab products in the Territory. The Company also evaluated whether certain options outlined within the mavrilimumab Collaboration Agreement represented material rights that would give rise to a performance obligation and concluded that none of the options convey a material right to Huadong and therefore are not considered separate performance obligations within the mavrilimumab Collaboration Agreement. The Company assessed the above promises and determined that the exclusive license for mavrilimumab in the Territory is reflective of a vendor-customer relationship and therefore represents a performance obligation. The exclusive license for mavrilimumab in the Territory is considered functional intellectual property and distinct from other promises under the Collaboration Agreement as Huadong can benefit from the license on its own or together with other readily available resources and the license is separately identifiable from the other promises. The clinical manufacturing supply of certain materials for mavrilimumab products in the Territory is considered distinct from the exclusive license for mavrilimumab as Huadong can benefit from the manufacturing services together with the license transferred by the Company at the inception of the Collaboration Agreement. Therefore, each represents a separate performance obligation within a contract with a customer at contract inception. The Company determined the transaction price at the inception of the mavrilimumab Collaboration Agreement which includes $10,000, consisting of the upfront payment. The Company also includes an estimate of variable consideration associated with the clinical manufacturing supply of certain materials when those materials are shipped. The Company determined that any variable consideration related to development and regulatory milestones is deemed fully constrained and therefore excluded from the transaction price due to the high degree of uncertainty and risk associated with these potential payments, as the Company determined that it could not assert that it was probable that a significant reversal in the amount of cumulative revenue recognized will not occur. The Company also determined that royalties and sales milestones relate solely to the licenses of intellectual property. Revenue related to these royalties and sales milestones will only be recognized when the associated sales occur, and relevant thresholds are met, under the sales or usage-based royalty exception of Topic 606. As noted above, the Company identified two performance obligations in the mavrilimumab Collaboration Agreement: (i) the delivery of the exclusive license for mavrilimumab in the Territory; and (ii) the clinical manufacturing supply of certain materials for mavrilimumab products in the Territory. The selling price of each performance obligation in the mavrilimumab Collaboration Agreement was determined based on the Company’s standalone selling price (“SSP”) with the objective of determining the price at which it would sell such an item if it were to be sold regularly on a standalone basis. The Company allocated the variable consideration related to the manufacturing obligations to the future clinical supply of mavrilimumab products in the Territory and the remaining fixed and variable consideration to the license obligation. The Company recognizes revenue for the license performance obligations at a point in time, that is upon transfer of the license to Huadong. As control of the license was transferred on the Effective Date and Huadong could begin to use and benefit from the license, the Company recognized $10,000 of collaboration revenue during the nine months ended September 30, 2022 under the mavrilimumab Collaboration Agreement. The Company will recognize revenue for the clinical manufacturing supply obligations at a point in time, that is upon each delivery of the supply to Huadong. Accounting for Rilonacept Collaboration Agreement As of the Effective Date, the Company identified the following material promises in the rilonacept Collaboration Agreement that were evaluated: delivery of (i) exclusive license for rilonacept in the Territory; (ii) clinical manufacturing supply of certain materials for rilonacept products in the Territory; and (iii) commercial manufacturing supply of certain material for rilonacept products in the Territory. The Company also evaluated whether certain options outlined within the rilonacept Collaboration Agreement represented material rights that would give rise to a performance obligation and concluded that none of the options convey a material right to Huadong and therefore are not considered separate performance obligations within the rilonacept Collaboration Agreement. The Company assessed the above promises and determined that there is one combined performance obligation for the exclusive license for rilonacept and clinical and commercial manufacturing obligations for rilonacept products in the Territory. Huadong cannot exploit the value of the exclusive license for rilonacept products in the Territory without receipt of supply as the exclusive license for rilonacept products in the Territory does not convey to Huadong the right to manufacture and therefore the Company has combined the exclusive license for rilonacept products in the Territory and the manufacturing obligations into one performance obligation. The Company determined the transaction price at the inception of the rilonacept Collaboration Agreement which includes $12,000, consisting of the upfront payment. The Company also includes an estimate of variable consideration associated with the clinical manufacturing supply of certain materials when those materials are shipped. The Company determined that any variable consideration related to development and regulatory milestones, sales milestones and royalties are deemed fully constrained and therefore excluded from the transaction price due to the high degree of uncertainty and risk associated with these potential payments, as the Company determined that it could not assert that it was probable that a significant reversal in the amount of cumulative revenue recognized will not occur. Royalties and sales milestones will be recognized as the Company delivers the commercial manufactured product to Huadong. Any changes in estimates may result in a cumulative catch-up based on the number of units of manufactured product delivered. As noted above, the Company identified a single combined performance obligation in the rilonacept Collaboration Agreement consisting of the exclusive license for rilonacept and clinical and commercial manufacturing obligations for rilonacept products in the Territory. The Company recognizes revenue for the combined performance obligation consisting of the exclusive license for rilonacept and clinical and commercial manufacturing obligations for rilonacept products in the Territory at a point in time, upon which control of materials are transferred to Huadong for each delivery of the associated materials. The Company currently expects to recognize the revenue over the life of the agreement. This estimate considers the timing of development and commercial activities under the rilonacept Collaboration Agreement and may be reduced or increased based on changes in the various activities. The Company has not recognized any revenue under the rilonacept Collaboration Agreement for the three and nine months ended September 30, 2022 as there has been no delivery of materials under the rilonacept Collaboration Agreement to date. The full transaction price of $12,000 is recorded in long-term deferred revenue, based upon timing of anticipated future shipments. The following table summarizes deferred revenue in connection with license and collaboration agreements for the nine months ended September 30, 2022: Balance at Balance at End Beginning of Period Additions Deductions of Period Nine Months Ended September 30, 2022 Huadong rilonacept $ — $ 12,000 $ — $ 12,000 Genentech vixarelimab — 14,290 — 14,290 Deferred revenue $ — $ 26,290 $ — $ 26,290 |
In-license, Acquisition and Col
In-license, Acquisition and Collaboration Agreements | 9 Months Ended |
Sep. 30, 2022 | |
License, Acquisition and Collaboration Agreements | |
In-license, Acquisition and Collaboration Agreements | 11. In-license, Acquisition and Collaboration Agreements Biogen Asset Purchase Agreement In September 2016, the Company entered into an asset purchase agreement (the “Biogen Agreement”) with Biogen MA Inc. (“Biogen”) to acquire all of Biogen’s right, title and interest in and to certain assets used in or relating to vixarelimab and other antibodies covered by certain patent rights, including patents and other intellectual property rights, clinical data, know-how, and clinical drug supply. In addition, Biogen granted to the Company a non-exclusive, sublicensable, worldwide license to certain background patent rights related to the vixarelimab program. The Company is obligated to use commercially reasonable efforts to develop and commercialize such acquired products. Under the Biogen Agreement, the Company is obligated to make milestone payments to Biogen of up to $179,000 upon the achievement of specified clinical and regulatory milestones in multiple indications in various territories, of which $165,000 remains as of September 30, 2022. Additionally, the Company could be obligated to make up to an aggregate of up to $150,000 of payments upon the achievement of specified annual net sales milestones and to pay tiered royalties on escalating tiers of annual net sales of licensed products starting in the high single-digit percentages and ending below the teens. The Company also agreed to pay certain obligations under third-party contracts retained by Biogen that relate to the vixarelimab program. Under these retained contracts, the Company paid a one-time upfront sublicense fee and is obligated to pay insignificant annual maintenance fees as well as clinical and regulatory milestone payments of up to an aggregate of $1,575. The Biogen Agreement will terminate upon the expiration of all payment obligations with respect to the last product in all countries in the territory. The Company has the right to terminate the agreement with 90 days’ prior written notice. Both parties may terminate by mutual written consent or in the event of material breach of the agreement by the other party that remains uncured for 90 days (or 30 days for payment-related breaches). In July 2017, the Company and Biogen entered into Amendment No. 1 to the Biogen Agreement, which clarified the scope of the antibodies subject to the Biogen Agreement. On August 2, 2022, the Company entered into Amendment No. 2 to the Biogen Agreement (the “Second Biogen Amendment”). Pursuant to the terms of the Second Biogen Amendment, commencing on the effective date of the Genentech License Agreement, certain defined terms in the Biogen Agreement were amended, including “Net Sales”, “Indication”, “Product”, “Combination Product” and “Valid Claim”. In addition, the tiered royalty rates to be paid by the Company to Biogen increased by an amount equal to less than one percent. Upon the termination or expiration of the Genentech License Agreement, the amendments to the terms of the Biogen Agreement, as set forth in the Second Biogen Amendment, will terminate and all terms of the Biogen Agreement will revert to the version of such terms in effect as of immediately prior to the effective date of the Genentech License Agreement. During the three and nine months ended September 30, 2022, the Company recorded research and development expense of $11 and $45, respectively, related to the annual maintenance in connection with the Biogen Agreement. During the three and nine months ended September 30, 2021, the Company recorded research and development expense of $14 and $42 respectively, related to the annual maintenance fee in connection with the retained contracts. Beth Israel Deaconess Medical Center License Agreement In 2019, the Company exercised the call option under the stock purchase option agreement with Primatope and acquired all of the outstanding securities of Primatope (the “Primatope Acquisition”). As a result of the Primatope Acquisition, the Company acquired the rights to an exclusive license to certain intellectual property rights controlled by Beth Israel Deaconess Medical Center, Inc. (“BIDMC”) to make, use, develop and commercialize KPL-404 (the “BIDMC Agreement”). Under the BIDMC Agreement, the Company is solely responsible for all development, regulatory and commercial activities and costs. The Company is also responsible for costs related to filing, prosecuting and maintaining the licensed patent rights. Under the BIDMC Agreement, the Company is obligated to pay an insignificant annual maintenance fee as well as clinical and regulatory milestone payments of up to an aggregate of $1,200 to BIDMC. The Company is also obligated to pay a low single-digit royalty on annual net sales of products licensed under the agreement. During the three and nine months ended September 30, 2022 and 2021, the Company did not record any research and development expense in connection with the BIDMC Agreement. Regeneron License Agreement In September 2017, the Company entered into a license agreement (the “Regeneron Agreement”) with Regeneron Pharmaceuticals, Inc. (“Regeneron”), pursuant to which the Company has been granted an exclusive license under certain intellectual property rights controlled by Regeneron to develop and commercialize ARCALYST worldwide, excluding the Middle East and North Africa, for all indications other than those in oncology and local administration to the eye or ear. Upon receiving positive data in RHAPSODY, the Company’s pivotal Phase 3 clinical trial of ARCALYST, Regeneron transferred the biologics license application, for ARCALYST to the Company. In March 2021, when the FDA granted approval of ARCALYST for the treatment of recurrent pericarditis and reduction in risk of recurrence in adults and children 12 years and older, the Company assumed the sales and distribution of ARCALYST for Cryopyrin-Associated Periodic Syndromes and Deficiency of Interleukin-1 Receptor Antagonist in the United States. The Company made a $20,000 payment in the first quarter of 2021 in connection with the achievement of a specified regulatory milestone event. The $20,000 milestone was accounted for as an intangible asset and will be amortized over the life of the underlying asset. Related amortization expense will be recorded as cost of goods sold in the Company’s consolidated statement of operations and comprehensive loss. The Company evenly splits profits on sales of ARCALYST with Regeneron, where profits are determined after deducting from net sales of ARCALYST certain costs related to the manufacturing and commercialization of ARCALYST. Such costs include but are not limited to (i) the Company’s cost of goods sold for product used, sold or otherwise distributed for patient use by the Company; (ii) customary commercialization expenses, including the cost of the Company’s field force, and (iii) the Company’s cost to market, advertise and otherwise promote ARCALYST, with such costs identified in subsection (iii) subject to specified limits. In addition, should there be a transfer of technology related to the manufacture of ARCALYST, then, to the extent permitted in accordance with the Regeneron Agreement, the fully-burdened costs incurred by each of the Company and Regeneron in performing (or having performed) such technology transfer shall also be deducted from net sales of ARCALYST to determine profit. The Company also evenly splits with Regeneron any proceeds received by the Company from any licensees, sublicensees and distributors in consideration for the sale, license or other disposition of rights with respect to ARCALYST, including upfront payments, milestone payments and royalties. For the three and nine months ended September 30, 2022, the Company recognized $4,623 and $16,549 respectively, of expenses related to the profit sharing agreement presented within collaboration expenses. The Company recorded $6,000 of profit sharing expense in February 2022 related to the rilonacept Collaboration Agreement. For the three and nine months ended September 30, 2021 the Company did not recognize any collaboration expenses related to the profit sharing agreement. Pursuant to the Regeneron Agreement, in September 2017, the parties entered into a clinical supply agreement under which Regeneron agreed to manufacture materials solely for the Company’s use in development activities. Pursuant to the Regeneron Agreement, during the year ended December 31, 2021, the Company entered into a commercial supply agreement under which Regeneron agreed to manufacture product for the Company’s use, including for commercial sales. The commercial supply agreement terminates upon the termination of the Regeneron Agreement or the date of completion of the transfer of technology related to the manufacture of ARCALYST. During the three and nine months ended September 30, 2022 and 2021, the Company did not incur any research and development expense related to the purchase of drug materials under the clinical supply agreement. As of September 30, 2022 and December 31, 2021, the Company recorded inventory of $14,621 and $3,675, respectively, related to the purchase of commercial product under the commercial supply agreement (see Note 5). As of September 30, 2022, the Company had non-cancelable purchase commitments under the commercial supply agreement (see Note 14). The Regeneron Agreement will expire when the Company is no longer developing or commercializing any licensed product under the Regeneron Agreement. Either party may terminate the agreement upon the other party’s insolvency or bankruptcy or for material breach of the agreement by the other party that remains uncured for 90 days (or 30 days for payment related breaches). Regeneron has the right to terminate the agreement if the Company suspends its development or commercialization activities for a consecutive 12 month period or does not grant a sublicense to a third party to perform such activities, or if the Company challenges any of the licensed patent rights. The Company may terminate the agreement at any time with one year’s written notice. The Company may also terminate the agreement with three months’ written notice if the licensed product is determined to have certain safety concerns. MedImmune License Agreement In December 2017, the Company entered into a license agreement (as amended from time to time, the “MedImmune Agreement”) with MedImmune, Limited (“MedImmune”), pursuant to which MedImmune granted the Company an exclusive, sublicensable, worldwide license to certain intellectual property rights to make, use, develop and commercialize mavrilimumab. Under the MedImmune Agreement, the Company also acquired reference rights to relevant manufacturing and regulatory documents and MedImmune’s existing supply of mavrilimumab drug substance and product. The Company is obligated to use commercially reasonable efforts to develop and commercialize the licensed products. The Company is obligated to make clinical, regulatory and initial sales milestone payments of up to $72,500 in aggregate for the first two indications, of which $57,500 remain as of September 30, 2022. In addition, the Company is obligated to make clinical and regulatory milestone payments of up to $15,000 in the aggregate for each subsequent indication. In July 2020, the Company entered into an amendment to the MedImmune Agreement to establish a new coronavirus field and defer the payment of certain development and regulatory milestones as applied to the new coronavirus field. The Company is obligated to make milestone payments to MedImmune of up to $85,000 upon the achievement of annual net sales thresholds up to, but excluding, $1,000,000 in annual net sales as well as additional milestone payments aggregating up to $1,100,000 upon the achievement of additional specified annual net sales thresholds starting at $1,000,000 and higher. The Company has also agreed to pay tiered royalties on escalating tiers of annual net sales of licensed products starting in the low double-digit percentages and ending at twenty percent. Royalty rates are subject to reductions upon certain events. The Company is solely responsible for all development, manufacturing, and commercial activities and costs of the licensed products, including clinical studies or other tests necessary to support the use of a licensed product. The Company is also responsible for costs related to the filing, prosecution and maintenance of the licensed patent rights. The MedImmune Agreement will expire upon the expiration of the royalty term in the last country for the last indication, as defined in the agreement. Either party may terminate the agreement upon the other party’s insolvency or bankruptcy or for material breach of the agreement by the other party that remains uncured for 90 days. MedImmune has the right to terminate the agreement if the Company challenges any of the licensed patent rights. The Company may terminate the agreement at any time upon 90 days’ prior written notice. During the three and nine months ended September 30, 2022 and 2021, the Company did not record research and development expense in connection with milestone payments due under the MedImmune Agreement. |
Earnings (Loss) per Share
Earnings (Loss) per Share | 9 Months Ended |
Sep. 30, 2022 | |
Earnings (Loss) per Share | |
Earnings (Loss) per Share | 12. Earnings (Loss) per Share The rights, including the liquidation and dividend rights, of the holders of Class A, Class B, Class A1 and Class B1 common shares are identical, except with respect to voting, transferability and conversion (see the Notes to Consolidated Financial Statements to our Form 10-K Basic and diluted EPS attributable to common shareholders was calculated as follows: Three Months Ended Nine Months Ended September 30, September 30, 2022 2021 2022 2021 Numerator: Net income (loss) attributable to common shareholders $ 224,093 $ (30,544) $ 178,902 $ (121,591) Denominator: Weighted-average basic shares outstanding 69,445,071 68,662,673 69,305,755 68,444,061 Effect of dilutive securities Options to purchase common shares 937,492 — 906,866 — Unvested RSUs 169,455 — 73,823 — Weighted-average diluted shares 70,552,018 68,662,673 70,286,444 68,444,061 Basic EPS $ 3.23 $ (0.44) $ 2.58 $ (1.78) Diluted EPS $ 3.18 $ (0.44) $ 2.55 $ (1.78) The Company’s unvested RSUs have been excluded from the computation of basic net loss per share attributable to common shareholders. Diluted earnings per share includes the assumed exercise of dilutive options and the assumed issuance of unvested RSUs and performance-based awards for which the performance condition has been met as of the date of determination, using the treasury stock method unless the effect is anti-dilutive. The treasury stock method assumes that proceeds, including cash received from the exercise of employee stock options and the average unrecognized compensation expense for unvested share-based compensation awards, would be used to purchase the Company’s common stock at the average market price during the period. For the three and nine months ended September 30, 2021 the Company’s potentially dilutive securities, which include options and unvested RSUs, have been excluded from the computation of diluted net loss per share attributable to common shareholders for the periods indicated as the effect would be to reduce the EPS attributable to common shareholders. Therefore, the weighted average number of common shares outstanding used to calculate both basic and diluted EPS attributable to common shareholders is the same. The Company excluded the following potential common shares, presented based on amounts outstanding at each period end, from the computation of diluted EPS attributable to common shareholders for the periods indicated because including them would have had an anti-dilutive effect: Three Months Ended Nine Months Ended September 30, September 30, 2022 2021 2022 2021 Options to purchase common shares 8,472,937 9,556,481 8,880,055 9,556,481 Unvested RSUs 837,457 801,154 1,547,383 801,154 9,310,394 10,357,635 10,427,438 10,357,635 |
Income Taxes
Income Taxes | 9 Months Ended |
Sep. 30, 2022 | |
Income Taxes | |
Income Taxes | 13. Income Taxes The Company is an exempted company incorporated under the laws of Bermuda. Under the current laws of Bermuda, income tax is not charged or levied on an exempted company’s income. As a result, the Company has not recorded any income tax benefits from losses incurred in Bermuda during each reporting period, and no net operating loss carryforwards will be available to the Company for those losses. The Company’s wholly owned U.S. subsidiaries, Kiniksa US and Primatope, are subject to federal and state income taxes in the United States. The Company’s wholly owned subsidiary Kiniksa UK, and its wholly owned subsidiaries, Kiniksa Germany, Kiniksa France, and Kiniksa Switzerland are subject to taxation in their respective countries. Certain of the Company’s subsidiaries, primarily Kiniksa US, operate under cost plus arrangements. Although Bermuda has no corporate income tax the Company’s income tax rate for the three and nine months ended September 30, 2022 is due to income subject to United Kingdom taxation and United States taxation under the Kiniksa US cost plus arrangements with the Company, and U.S. federal and state research tax credits (“R&D credits”). Income tax benefit for the three and nine months ended September 30, 2022 was $177,358 and $174,717, respectively. The benefit for income taxes is primarily driven by the release of the valuation allowance on the Company’s UK deferred tax assets in the third quarter. Management regularly reassesses the valuation allowance on the Company’s deferred income tax assets. Valuation allowances require an assessment of both positive and negative evidence when determining whether it is more likely than not that the Company will be able to recover its deferred tax assets. Such assessment is required on a jurisdiction-by-jurisdiction basis. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. In the third quarter of 2022, the Company assessed the valuation allowance on its UK deferred tax assets and considered positive evidence, including cumulative UK income in recent years, continued commercial execution of ARCALYST, and expectations regarding future probability. After assessing both the positive evidence and negative evidence, the Company determined it was more likely than not that its UK deferred tax assets would be realized in the future and released the associated valuation allowance as of September 30, 2022. This resulted in a benefit of $185,843. As of September 30, 2022, the Company maintained a full valuation allowance against its U.S. deferred tax assets. There are no material deferred tax assets in the jurisdictions outside Kiniksa US and Kiniksa UK. The Company transferred all of its rights, title and interest in, among other things, certain contracts (including the Biogen Agreement), intellectual property rights, product filings and approvals and other information, plans and materials owned or controlled by the Company insofar as they related exclusively or primarily to vixarelimab to Kiniksa UK in July 2022 pursuant to an asset transfer agreement between the Company and Kiniksa UK for the consideration described therein. The Company did not incur any material tax liabilities in connection with the transfer and Kiniksa UK received a stepped up basis in the property. |
Commitments and Contingencies
Commitments and Contingencies | 9 Months Ended |
Sep. 30, 2022 | |
Commitments and Contingencies | |
Commitments and Contingencies | 14. Commitments and Contingencies License Agreements The Company entered into license agreements with various parties under which it is obligated to make contingent and non-contingent payments (see Note 11). Manufacturing Commitments The Company entered into a commercial supply agreement with Regeneron to provide both clinical supply and commercial product (see Note 11). The Company entered into agreements with several CMOs to provide the Company with preclinical and clinical trial materials. As of September 30, 2022, the Company had committed to minimum payments under these agreements totaling $33,019 all of which are due within one year. Indemnification Agreements The Company is not aware of any claims under indemnification arrangements that are expected to have a material effect on its financial position, results of operations or cash flows, and it has not accrued any liabilities related to such obligations in its consolidated financial statements as of September 30, 2022 or December 31, 2021. Legal Proceedings The Company is not a party to any material litigation and does not have contingency reserves established for any litigation liabilities. |
Summary of Significant Accoun_2
Summary of Significant Accounting Policies (Policies) | 9 Months Ended |
Sep. 30, 2022 | |
Summary of Significant Accounting Policies | |
Principles of Consolidation | Principles of Consolidation The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) and include the accounts of the Company and its wholly owned subsidiaries, Kiniksa Pharmaceuticals Corp. (“Kiniksa US”), Primatope Therapeutics, Inc. (“Primatope”) and Kiniksa Pharmaceuticals (UK), Ltd. (“Kiniksa UK”) as well as the subsidiaries of Kiniksa UK, Kiniksa Pharmaceuticals (Germany) GmbH (“Kiniksa Germany”), Kiniksa Pharmaceuticals (France) SARL (“Kiniksa France”), and Kiniksa Pharmaceuticals GmbH (“Kiniksa Switzerland”), after elimination of all significant intercompany accounts and transactions. |
Use of Estimates | Use of Estimates The preparation of the Company’s consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting period. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, the recognition of revenue, the capitalization of inventory, the accrual for research and development expenses, the valuation of share-based awards and the realizability of deferred tax assets. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ from those estimates. |
Unaudited Interim Consolidated Financial Information | Unaudited Interim Consolidated Financial Information The accompanying unaudited consolidated financial statements have been prepared in accordance with GAAP for interim financial information. The accompanying unaudited consolidated financial statements do not include all of the information and footnotes required by GAAP for complete consolidated financial statements. The information included in this quarterly report on Form 10-Q should be read in conjunction with the Company’s audited consolidated financial statements and the accompanying notes included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021 (the “2021 Form 10-K”). The Company’s accounting policies are described in the Notes to Consolidated Financial Statements in the Company’s 2021 Form 10-K and updated, as necessary, in this report. The accompanying year-end consolidated balance sheet was derived from audited financial statements but does not include all disclosures required by GAAP. The unaudited interim consolidated financial statements have been prepared on the same basis as the audited annual consolidated financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary for the fair statement of the Company’s financial position as of September 30, 2022 and the results of its operations for the three and nine months ended September 30, 2022 and 2021, the changes in its shareholders’ equity for the three and nine months ended September 30, 2022 and 2021 and its cash flows for the nine months ended September 30, 2022 and 2021. The results for the three and nine months ended September 30, 2022 are not necessarily indicative of results to be expected for the year ending December 31, 2022, any other interim periods or any future year or period. |
Liquidity | Liquidity The Company has evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date the consolidated financial statements are issued. As of September 30, 2022, the Company had an accumulated deficit of $496,495. During the nine months ended September 30, 2022, the Company reported net income of $178,902 and provided $17,383 cash in operating activities. As of September 30, 2022, the Company had cash, cash equivalents and short-term investments of $200,724. Based on its current operating plan, the Company expects that its cash, cash equivalents and short-term investments will be sufficient to fund its operations and capital expenditure requirements for at least twelve months from the issuance date of these consolidated financial statements. The future viability of the Company beyond that point is dependent on its ability to fund its operations through sales of ARCALYST and/or raise additional capital, as needed. If the Company is unable to grow sales of ARCALYST in future periods, the Company would need to seek additional financing through public or private securities offerings, debt financings, government funding or grants, or other sources, which may include licensing, collaborations or other strategic transactions or arrangements. Although the Company has been successful in raising capital in the past, there is no assurance that it will be successful in obtaining such additional financing on terms acceptable to the Company, if at all. If the Company is unable to obtain funding, the Company could be forced to delay, reduce or eliminate some or all of its commercialization efforts, research and development programs for product candidates or product portfolio expansion, which could adversely affect its business prospects, or the Company may be unable to continue operations. |
Revenue Recognition | ASC Topic 606, Revenue from Contracts with Customers (“ASC 606”) outlines a five-step process for recognizing revenue from contracts with customers: (i) identify the contract with the customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, (iv) allocate the transaction price to the separate performance obligations in the contract, and (v) recognize revenue associated with the performance obligations as they are satisfied. The Company only applies the five-step model to contracts when it is probable that the Company will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. Once a contract is determined to be within the scope of ASC 606, the Company determines the performance obligations that are distinct. The Company recognizes as revenues the amount of the transaction price that is allocated to each respective performance obligation when the performance obligation is satisfied. Generally, the Company’s performance obligations are transferred to customers at a point in time, typically upon delivery of the product to the customer. ASC 606 requires entities to record a contract asset when a performance obligation has been satisfied or partially satisfied, but the amount of consideration has not yet been received because the receipt of the consideration is conditioned on something other than the passage of time. ASC 606 also requires an entity to present a revenue contract as a contract liability in instances when a customer pays consideration, or an entity has a right to an amount of consideration that is unconditional (e.g., receivable), before the entity transfers a good or service to the customer. |
Collaboration Revenue | Collaboration Revenue The Company analyzes its collaboration arrangements to assess whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards dependent on the commercial success of such activities and therefore within the scope of ASC Topic 808, Collaborative Arrangements (“Topic 808”). This assessment is performed throughout the life of the arrangement based on changes in the responsibilities of all parties in the arrangement. For collaboration arrangements within the scope of Topic 808 that contain multiple elements, the Company first determines which elements of the collaboration are deemed to be within the scope of Topic 808 and which elements of the collaboration are more reflective of a vendor-customer relationship and therefore within the scope of Topic 606. For elements of collaboration arrangements that are accounted for pursuant to ASC 606, we identify the performance obligations and allocate the total consideration we expect to receive on a relative standalone selling price basis to each performance obligation. Variable consideration such as performance-based milestones will be included in the total consideration if we expect to receive such consideration and if it is probable that the inclusion of the variable consideration will not result in a significant reversal in the cumulative amount of revenue recognized under the arrangement. Our estimate of the total consideration we expect to receive under each collaboration arrangement is updated for each reporting period, and any adjustments to revenue are recorded on a cumulative catch-up basis. We exclude sales-based royalty and milestone payments from the total consideration we expect to receive until the underlying sales occur because the license to our intellectual property is deemed to be the predominant item to which the royalties or milestones relate as it is the primary driver of value in our collaboration arrangements. Key assumptions to determine the standalone selling price may include forecasted revenues, development timelines, reimbursement rates for personnel costs, discount rates and probabilities of technical and regulatory success. We recognize revenue associated with each performance obligation as the control over the promised goods or services transfer to our collaboration partner which occurs either at a point in time or over time. If control transfers over time, revenue is recognized by using a method of measuring progress that best depicts the transfer of goods or services. We evaluate the measure of progress and related inputs each reporting period and any resulting adjustments to revenue are recorded on a cumulative catch-up basis. Consideration received that does not meet the requirements to satisfy ASC 808 or ASC 606 revenue recognition criteria is recorded as deferred revenue in the accompanying consolidated balance sheets, classified as either short-term (less than 12 months) or long-term (more than 12 months) deferred revenue based on our best estimate of when such revenue will be recognized. There have been no other material changes to the significant accounting policies previously disclosed in the Company’s 2021 Form 10-K. |
Recently Adopted Accounting Pronouncements | Recently Adopted Accounting Pronouncements |
Fair Value of Financial Asset_2
Fair Value of Financial Assets and Liabilities (Tables) | 9 Months Ended |
Sep. 30, 2022 | |
Fair Value of Financial Assets and Liabilities | |
Schedule of financial assets and liabilities measured at fair value on a recurring basis | Fair Value Measurements as of September 30, 2022 Using: Level 1 Level 2 Level 3 Total Assets: Cash equivalents — money market funds $ 39,533 $ — $ — $ 39,533 Short-term investments — U.S. Treasury notes — 24,963 — 24,963 $ 39,533 $ 24,963 $ — $ 64,496 Fair Value Measurements as of December 31, 2021 Using: Level 1 Level 2 Level 3 Total Assets: Cash equivalents — money market funds $ 94,324 $ — $ — $ 94,324 Short-term investments — U.S. Treasury notes — 59,731 — 59,731 $ 94,324 $ 59,731 $ — $ 154,055 |
Schedule of short-term investments | Gross Gross Amortized Unrealized Unrealized Credit Fair Cost Gains Losses Losses Value September 30, 2022 Short-term investments — U.S. Treasury notes $ 24,986 $ — $ (23) $ — $ 24,963 $ 24,986 $ — $ (23) $ — $ 24,963 Gross Gross Amortized Unrealized Unrealized Credit Fair Cost Gains Losses Losses Value December 31, 2021 Short-term investments — U.S. Treasury notes $ 59,745 $ 1 $ (15) $ — $ 59,731 $ 59,745 $ 1 $ (15) $ — $ 59,731 |
Product Revenue, Net (Tables)
Product Revenue, Net (Tables) | 9 Months Ended |
Sep. 30, 2022 | |
Product Revenue, Net | |
Schedule of product revenue, net | Three Months Ended Nine Months Ended September 30, September 30, 2022 2021 2022 2021 Product revenue, net $ 33,424 $ 12,095 $ 82,585 $ 19,799 |
Schedule of balances and activity of the product revenue allowance and reserve categories | Contractual Government Adjustments Rebates Returns Total Balance at December 31, 2021 $ 515 $ 719 $ 101 $ 1,335 Current provisions relating to sales in the current year 4,993 3,011 227 8,231 Payments/returns relating to sales in the current year (3,797) (1,659) — (5,456) Payments/returns relating to sales in the prior years (295) (535) — (830) Balance at September 30, 2022 $ 1,416 $ 1,536 $ 328 $ 3,280 September 30, December 31, 2022 2021 Reduction of accounts receivable $ (157) $ (50) Components of other current liabilities 3,437 1385 Total revenue-related reserves $ 3,280 $ 1,335 |
Inventory (Tables)
Inventory (Tables) | 9 Months Ended |
Sep. 30, 2022 | |
Inventory | |
Schedule of inventory | September 30, December 31, 2022 2021 Raw materials $ — $ — Work-in-process — — Finished Goods 14,621 3,675 $ 14,621 $ 3,675 |
Property and Equipment, Net (Ta
Property and Equipment, Net (Tables) | 9 Months Ended |
Sep. 30, 2022 | |
Property and Equipment, Net | |
Schedule of property and equipment, net | September 30, December 31, 2022 2021 Furniture, fixtures and vehicles $ 224 $ 62 Computer hardware and software 345 341 Leasehold improvements 3,931 3,931 Lab equipment 4,068 4,249 Construction in progress 32 166 Total property and equipment 8,600 8,749 Less: Accumulated depreciation (6,605) (5,915) Total property and equipment, net $ 1,995 $ 2,834 |
Intangible Assets (Tables)
Intangible Assets (Tables) | 9 Months Ended |
Sep. 30, 2022 | |
Intangible Assets | |
Schedule of intangible assets, net of accumulated amortization, impairment charges, and adjustments | As of September 30, 2022 As of December 31, 2021 Estimated Accumulated Accumulated life Cost Amortization Net Cost Amortization Net Regulatory milestone 20 years $ 20,000 $ 1,500 $ 18,500 $ 20,000 $ 750 $ 19,250 $ 20,000 $ 1,500 $ 18,500 $ 20,000 $ 750 $ 19,250 |
Accrued Expenses (Tables)
Accrued Expenses (Tables) | 9 Months Ended |
Sep. 30, 2022 | |
Accrued Expenses | |
Schedule of accrued expenses | September 30, December 31, 2022 2021 Accrued research and development expenses $ 13,559 $ 24,977 Accrued employee compensation and benefits 8,316 8,916 Accrued collaboration expenses 4,660 835 Accrued legal, commercial and professional fees 3,754 2,933 Other 579 370 $ 30,868 $ 38,031 |
Share-Based Compensation (Table
Share-Based Compensation (Tables) | 9 Months Ended |
Sep. 30, 2022 | |
Share-Based Compensation | |
Schedule of share option activity under the Plans | Weighted Number of Average Shares Exercise Price Outstanding as of December 31, 2021 9,226,846 $ 14.14 Granted 2,792,460 $ 11.22 Exercised (226,230) $ 5.81 Forfeited (1,468,620) $ 15.59 Outstanding as of September 30, 2022 10,324,456 $ 13.32 Share options exercisable as of September 30, 2022 5,525,898 $ 13.52 Share options unvested as of September 30, 2022 4,798,558 $ 13.10 |
Schedule of restricted share activity | Weighted Average Number of Grant Date Shares Fair Value Unvested RSUs as of December 31, 2021 885,021 $ 15.72 Granted 1,318,583 $ 10.71 Vested (229,151) $ 15.79 Forfeited (320,710) $ 14.08 Unvested RSUs as of September 30, 2022 1,653,743 $ 13.17 |
Schedule of share-based compensation expense was classified in the consolidated statements of operations and comprehensive loss | Three Months Ended Nine Months Ended September 30, September 30, 2022 2021 2022 2021 Cost of goods sold $ 164 $ 62 $ 456 $ 101 Research and development expenses 1,532 1,912 5,116 6,469 Selling, general and administrative expenses 4,345 4,225 13,176 12,472 $ 6,041 $ 6,199 $ 18,748 $ 19,042 |
Out-Licensing Agreements (Table
Out-Licensing Agreements (Tables) | 9 Months Ended |
Sep. 30, 2022 | |
Out-licensing Agreements | |
Schedule of deferred revenue in connection with collaboration agreements | Balance at Balance at End Beginning of Period Additions Deductions of Period Nine Months Ended September 30, 2022 Huadong rilonacept $ — $ 12,000 $ — $ 12,000 Genentech vixarelimab — 14,290 — 14,290 Deferred revenue $ — $ 26,290 $ — $ 26,290 |
Earnings (Loss) per Share (Tabl
Earnings (Loss) per Share (Tables) | 9 Months Ended |
Sep. 30, 2022 | |
Earnings (Loss) per Share | |
Schedule of basic and diluted EPS attributable to common shareholders | Three Months Ended Nine Months Ended September 30, September 30, 2022 2021 2022 2021 Numerator: Net income (loss) attributable to common shareholders $ 224,093 $ (30,544) $ 178,902 $ (121,591) Denominator: Weighted-average basic shares outstanding 69,445,071 68,662,673 69,305,755 68,444,061 Effect of dilutive securities Options to purchase common shares 937,492 — 906,866 — Unvested RSUs 169,455 — 73,823 — Weighted-average diluted shares 70,552,018 68,662,673 70,286,444 68,444,061 Basic EPS $ 3.23 $ (0.44) $ 2.58 $ (1.78) Diluted EPS $ 3.18 $ (0.44) $ 2.55 $ (1.78) |
Schedule of anti-dilutive securities excluded from the computation of diluted EPS attributable to common shareholders | Three Months Ended Nine Months Ended September 30, September 30, 2022 2021 2022 2021 Options to purchase common shares 8,472,937 9,556,481 8,880,055 9,556,481 Unvested RSUs 837,457 801,154 1,547,383 801,154 9,310,394 10,357,635 10,427,438 10,357,635 |
Nature of the Business and Ba_2
Nature of the Business and Basis of Presentation (Details) - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | |||||||
Sep. 30, 2022 | Jun. 30, 2022 | Mar. 31, 2022 | Sep. 30, 2021 | Jun. 30, 2021 | Mar. 31, 2021 | Sep. 30, 2022 | Sep. 30, 2021 | Dec. 31, 2021 | |
Liquidity | |||||||||
Accumulated deficit | $ 496,495 | $ 496,495 | $ 675,397 | ||||||
Net income (loss) | 224,093 | $ (19,981) | $ (25,210) | $ (30,544) | $ (41,563) | $ (49,484) | 178,902 | $ (121,591) | |
Cash provided by operations | 17,383 | $ (107,414) | |||||||
Cash, cash equivalents and short-term investments | $ 200,724 | $ 200,724 |
Fair Value of Financial Asset_3
Fair Value of Financial Assets and Liabilities (Details) $ in Thousands | 9 Months Ended | 12 Months Ended |
Sep. 30, 2022 USD ($) security | Dec. 31, 2021 USD ($) security | |
Fair Value, Assets Transfers | ||
Fair value of assets transferred from Level 1 to Level 2 | $ 0 | $ 0 |
Fair value of assets transferred from Level 2 to Level 1 | 0 | 0 |
Fair value of asset transfer into Level 3 | 0 | 0 |
Fair value of asset transfer out of Level 3 | $ 0 | $ 0 |
Number of securities in an unrealized loss position | security | 6 | 11 |
Securities in unrealized loss position | $ 22,466 | $ 49,739 |
U.S. Treasury Notes | ||
Assets - Fair Value | ||
Short-term investments | 24,963 | 59,731 |
Short-term investments | ||
Amortized Cost | 24,986 | 59,745 |
Gross Unrealized Gains | 1 | |
Gross Unrealized Losses | (23) | (15) |
U.S. Treasury Notes | Short-term Investments | ||
Assets - Fair Value | ||
Short-term investments | 24,963 | 59,731 |
Short-term investments | ||
Amortized Cost | 24,986 | 59,745 |
Gross Unrealized Gains | 1 | |
Gross Unrealized Losses | (23) | (15) |
Fair Value | Recurring basis | ||
Assets - Fair Value | ||
Assets | 64,496 | 154,055 |
Fair Value | Recurring basis | Money Market Funds | ||
Assets - Fair Value | ||
Cash equivalents | 39,533 | 94,324 |
Fair Value | Recurring basis | U.S. Treasury Notes | ||
Assets - Fair Value | ||
Short-term investments | 24,963 | 59,731 |
Fair Value | Recurring basis | Level 1 | ||
Assets - Fair Value | ||
Assets | 39,533 | 94,324 |
Fair Value | Recurring basis | Level 1 | Money Market Funds | ||
Assets - Fair Value | ||
Cash equivalents | 39,533 | 94,324 |
Fair Value | Recurring basis | Level 2 | ||
Assets - Fair Value | ||
Assets | 24,963 | 59,731 |
Fair Value | Recurring basis | Level 2 | U.S. Treasury Notes | ||
Assets - Fair Value | ||
Short-term investments | $ 24,963 | $ 59,731 |
Product Revenue, Net (Details)
Product Revenue, Net (Details) - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2022 | Sep. 30, 2021 | Sep. 30, 2022 | Sep. 30, 2021 | |
Product revenue | ||||
Product revenue, net | $ 99,135 | $ 12,095 | $ 158,296 | $ 19,799 |
Contractual Adjustments | ||||
Balance at beginning of period | 515 | |||
Current provisions relating to sales in the current year | 4,993 | |||
Payments/returns relating to sales in the current year | (3,797) | |||
Payments/returns relating to sales in the prior years | (295) | |||
Balance at end of period | 1,416 | 1,416 | ||
Government Rebates | ||||
Balance at beginning of period | 719 | |||
Current provisions relating to sales in the current year | 3,011 | |||
Payments/returns relating to sales in current year | (1,659) | |||
Payments/returns relating to sales in the prior years | (535) | |||
Balance at end of period | 1,536 | 1,536 | ||
Returns | ||||
Balance at beginning of period | 101 | |||
Current provision relating sales in the current year | 227 | |||
Balance at end of period | 328 | 328 | ||
Total | ||||
Balance at beginning of period | 1,335 | |||
Current provisions relating to sales in the current year | 8,231 | |||
Payments/returns relating to sales in the current year | (5,456) | |||
Payments/returns relating to sales in the prior years | (830) | |||
Balance at end of period | 3,280 | 3,280 | ||
Product revenue, net | ||||
Product revenue | ||||
Product revenue, net | $ 33,424 | $ 12,095 | $ 82,585 | $ 19,799 |
Product Revenue, Net - Revenue
Product Revenue, Net - Revenue Related Reserves in Balance Sheet (Details) - USD ($) $ in Thousands | Sep. 30, 2022 | Dec. 31, 2021 |
Revenue-related reserves | ||
Revenue-related reserves | $ 3,280 | $ 1,335 |
Accounts receivable, net | 11,159 | 3,985 |
Accounts receivable, net | ||
Revenue-related reserves | ||
Revenue-related reserves | (157) | (50) |
Other current liabilities | ||
Revenue-related reserves | ||
Revenue-related reserves | $ 3,437 | $ 1,385 |
Inventory (Details)
Inventory (Details) - USD ($) $ in Thousands | Sep. 30, 2022 | Dec. 31, 2021 |
Inventory | ||
Finished goods | $ 14,621 | $ 3,675 |
Total inventory | $ 14,621 | $ 3,675 |
Property and Equipment, Net (De
Property and Equipment, Net (Details) - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | |||
Sep. 30, 2022 | Sep. 30, 2021 | Sep. 30, 2022 | Sep. 30, 2021 | Dec. 31, 2021 | |
Property and Equipment, Net | |||||
Total property and equipment | $ 8,600 | $ 8,600 | $ 8,749 | ||
Less: Accumulated depreciation | (6,605) | (6,605) | (5,915) | ||
Total property and equipment, net | 1,995 | 1,995 | 2,834 | ||
Depreciation expense | 177 | $ 373 | 885 | $ 1,079 | |
Furniture, fixtures, and vehicles | |||||
Property and Equipment, Net | |||||
Total property and equipment | 224 | 224 | 62 | ||
Computer hardware and software | |||||
Property and Equipment, Net | |||||
Total property and equipment | 345 | 345 | 341 | ||
Leasehold improvements | |||||
Property and Equipment, Net | |||||
Total property and equipment | 3,931 | 3,931 | 3,931 | ||
Lab equipment | |||||
Property and Equipment, Net | |||||
Total property and equipment | 4,068 | 4,068 | 4,249 | ||
Construction in progress | |||||
Property and Equipment, Net | |||||
Total property and equipment | $ 32 | $ 32 | $ 166 |
Intangible Assets - Finite-live
Intangible Assets - Finite-lived Intangible Assets (Details) - USD ($) $ in Thousands | 9 Months Ended | |
Sep. 30, 2022 | Dec. 31, 2021 | |
Finite-lived intangible asset | ||
Cost | $ 20,000 | $ 20,000 |
Accumulated Amortization | 1,500 | 750 |
Net intangible assets | $ 18,500 | 19,250 |
Regulatory milestone | ||
Finite-lived intangible asset | ||
Estimated life | 20 years | |
Cost | $ 20,000 | 20,000 |
Accumulated Amortization | 1,500 | 750 |
Net intangible assets | $ 18,500 | $ 19,250 |
Accrued Expenses (Details)
Accrued Expenses (Details) - USD ($) $ in Thousands | Sep. 30, 2022 | Dec. 31, 2021 |
Accrued Expenses | ||
Accrued research and development expenses | $ 13,559 | $ 24,977 |
Accrued employee compensation and benefits | 8,316 | 8,916 |
Accrued legal and professional fees | 3,754 | 2,933 |
Accrued collaboration expenses | 4,660 | 835 |
Other | 579 | 370 |
Accrued expenses | $ 30,868 | $ 38,031 |
Share Based Compensation (Detai
Share Based Compensation (Details) - shares | 9 Months Ended | ||
Jan. 01, 2022 | Sep. 30, 2022 | Dec. 31, 2021 | |
Restricted Share Units (RSUs) | |||
Share-based compensation | |||
RSUs Granted | 1,318,583 | ||
Stock options | Class A common shares | |||
Share-based compensation | |||
Shares outstanding (in shares) | 10,324,456 | 9,226,846 | |
Number of options granted | 2,792,460 | ||
2018 Plan | |||
Share-based compensation | |||
Number of common shares available for future grant | 4,117,546 | ||
2018 Plan | Class A common shares | Maximum | |||
Share-based compensation | |||
Additional shares authorized | 2,762,416 | ||
2015 Plan | Class A common shares | |||
Share-based compensation | |||
Shares outstanding (in shares) | 2,029,355 | ||
2018 ESPP | Class A common shares | |||
Share-based compensation | |||
Number of common shares available for future grant | 604,290 | ||
2018 ESPP | Class A common shares | Maximum | |||
Share-based compensation | |||
Additional shares authorized | 90,000 |
Share-Based Compensation - Opti
Share-Based Compensation - Options (Details) - Class A common shares - Stock options | 9 Months Ended |
Sep. 30, 2022 $ / shares shares | |
Number of Shares | |
Outstanding, beginning of the period | shares | 9,226,846 |
Granted | shares | 2,792,460 |
Exercised | shares | (226,230) |
Forfeited | shares | (1,468,620) |
Outstanding, end of the period | shares | 10,324,456 |
Options exercisable | shares | 5,525,898 |
Options unvested | shares | 4,798,558 |
Weighted Average Grant Date Fair Value | |
Outstanding, beginning of the period | $ / shares | $ 14.14 |
Granted | $ / shares | 11.22 |
Exercised | $ / shares | 5.81 |
Forfeited | $ / shares | 15.59 |
Outstanding, end of the period | $ / shares | 13.32 |
Options exercisable | $ / shares | 13.52 |
Options unvested | $ / shares | $ 13.10 |
Share-Based Compensation - Rest
Share-Based Compensation - Restricted Shares and RSUs (Details) - USD ($) $ / shares in Units, $ in Thousands | 1 Months Ended | 3 Months Ended | 9 Months Ended | ||
Mar. 31, 2021 | Sep. 30, 2022 | Sep. 30, 2021 | Sep. 30, 2022 | Sep. 30, 2021 | |
Share-based compensation | |||||
Share-based compensation expense | $ 6,041 | $ 6,199 | $ 18,748 | $ 19,042 | |
Restricted Share Units (RSUs) | |||||
Share-based compensation | |||||
Share-based compensation expense | $ 1,146 | $ 838 | $ 2,697 | $ 2,868 | |
Number of shares | |||||
Beginning of the period | 885,021 | ||||
Granted | 1,318,583 | ||||
Vested | (229,151) | ||||
Forfeited | (320,710) | ||||
End of the period | 1,653,743 | 1,653,743 | |||
Weighted Average Fair Value at Issuance | |||||
Beginning of the period | $ 15.72 | ||||
Granted | 10.71 | ||||
Vested | 15.79 | ||||
Forfeited | 14.08 | ||||
End of the period | $ 13.17 | $ 13.17 | |||
Time-based RSUs | |||||
Share-based compensation | |||||
Vesting percentage | 25% |
Share-Based Compensation - Clas
Share-Based Compensation - Classification of Expense (Details) - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2022 | Sep. 30, 2021 | Sep. 30, 2022 | Sep. 30, 2021 | |
Share-based compensation | ||||
Share-based compensation expense | $ 6,041 | $ 6,199 | $ 18,748 | $ 19,042 |
Cost of goods sold | ||||
Share-based compensation | ||||
Share-based compensation expense | 164 | 62 | 456 | 101 |
Research and development expenses | ||||
Share-based compensation | ||||
Share-based compensation expense | 1,532 | 1,912 | 5,116 | 6,469 |
Selling, general and administrative expenses | ||||
Share-based compensation | ||||
Share-based compensation expense | 4,345 | 4,225 | 13,176 | 12,472 |
Stock options | ||||
Share-based compensation | ||||
Total unrecognized compensation cost | 40,360 | $ 40,360 | ||
Expenses expected to be recognized over a weighted average remaining period | 2 years 8 months 23 days | |||
Restricted Share Units (RSUs) | ||||
Share-based compensation | ||||
Share-based compensation expense | 1,146 | $ 838 | $ 2,697 | $ 2,868 |
Total unrecognized compensation cost | $ 17,821 | $ 17,821 | ||
Expenses expected to be recognized over a weighted average remaining period | 3 years 4 months 17 days |
Out-Licensing Agreements (Detai
Out-Licensing Agreements (Details) $ in Thousands | 3 Months Ended | 9 Months Ended | ||||
Aug. 02, 2022 USD ($) item | Feb. 21, 2022 USD ($) item agreement | Sep. 30, 2022 USD ($) | Sep. 30, 2021 USD ($) | Sep. 30, 2022 USD ($) | Sep. 30, 2021 USD ($) | |
Collaborative agreements | ||||||
Product revenue, net | $ 99,135 | $ 12,095 | $ 158,296 | $ 19,799 | ||
License and collaboration revenue | ||||||
Collaborative agreements | ||||||
Product revenue, net | $ 65,711 | 75,711 | ||||
Collaboration Agreements | Huadong rilonacept | ||||||
Collaborative agreements | ||||||
Notice period to terminate the agreement | 12 months | |||||
Collaboration Agreements | Huadong rilonacept | ||||||
Collaborative agreements | ||||||
Number of agreements entered into | agreement | 2 | |||||
Upfront payments received | $ 22,000 | |||||
Term of agreement for royalty payments | 12 years | |||||
Notice period to terminate the agreement if there is no material development or commercialization activities with respect to the licensed product in China | 60 days | |||||
Collaboration Agreements | Huadong rilonacept | Minimum | ||||||
Collaborative agreements | ||||||
Time period threshold of continuous material development or commercialization activities in China that, if not met, can trigger the right for the Company to terminate the agreement | 6 months | |||||
Territory License - Rilonacept | Huadong rilonacept | ||||||
Collaborative agreements | ||||||
Upfront payments received | $ 12,000 | |||||
Number of performance obligations in an agreement | item | 1 | |||||
Transaction price | 12,000 | |||||
Territory License - Rilonacept | Huadong rilonacept | Maximum | ||||||
Collaborative agreements | ||||||
Payments to be received by the company upon the achievement of specified development, regulatory and sales milestones | $ 70 | |||||
Territory License - Mavrilimumab | License and collaboration revenue | ||||||
Collaborative agreements | ||||||
Product revenue, net | 10,000 | |||||
Territory License - Mavrilimumab | Huadong rilonacept | ||||||
Collaborative agreements | ||||||
Upfront payments received | $ 10,000 | |||||
Number of performance obligations in an agreement | item | 2 | |||||
Transaction price | 10,000 | |||||
Territory License - Mavrilimumab | Huadong rilonacept | Maximum | ||||||
Collaborative agreements | ||||||
Payments to be received by the company upon the achievement of specified development, regulatory and sales milestones | $ 576 | |||||
Worldwide License - Vixarelimab | Genentech | ||||||
Collaborative agreements | ||||||
Upfront payments received | $ 80,000 | |||||
Payments to be received by the company upon delivery of certain materials | 20,000 | |||||
Milestone receipts | $ 600,000 | |||||
Number of performance obligations in an agreement | item | 4 | |||||
Product revenue, net | $ 65,711 | |||||
Transaction price | $ 80,000 |
Out-Licensing Agreements - Defe
Out-Licensing Agreements - Deferred Revenue (Details) $ in Thousands | 9 Months Ended | 21 Months Ended |
Sep. 30, 2022 USD ($) | Sep. 30, 2022 USD ($) | |
Collaborative agreements | ||
Long-term Deferred Revenue | $ 14,198 | $ 14,198 |
Additions | 26,290 | |
Balance at end of period | 26,290 | 26,290 |
Territory License - Rilonacept | Huadong rilonacept | ||
Collaborative agreements | ||
Long-term Deferred Revenue | 12,000 | 12,000 |
Additions | 12,000 | |
Balance at end of period | 12,000 | 12,000 |
Territory License - Rilonacept | Huadong rilonacept | License and collaboration revenue | ||
Collaborative agreements | ||
Revenue recognized | 0 | |
Worldwide License - Vixarelimab | Genentech | ||
Collaborative agreements | ||
Additions | 14,290 | |
Balance at end of period | $ 14,290 | $ 14,290 |
In-license, Acquisition and C_2
In-license, Acquisition and Collaboration Agreements - Biogen Asset Purchase Agreement (Details) - USD ($) $ in Thousands | 1 Months Ended | 3 Months Ended | 9 Months Ended | ||||
Aug. 02, 2022 | Sep. 30, 2017 | Sep. 30, 2016 | Sep. 30, 2022 | Sep. 30, 2021 | Sep. 30, 2022 | Sep. 30, 2021 | |
License and Acquisition Agreements | |||||||
Uncured period which causes termination of the agreement, due to insolvency or bankruptcy or for material breach of the agreement by the other party that remains uncured | 90 days | ||||||
Notice period to terminate the agreement under payment-related breaches | 30 days | ||||||
Research and development | $ 16,485 | $ 19,236 | $ 51,100 | $ 71,864 | |||
Maximum | |||||||
License and Acquisition Agreements | |||||||
Royalty rate increase (percentage) | 1% | ||||||
Asset Purchase Agreement | Biogen | |||||||
License and Acquisition Agreements | |||||||
Remaining milestone payments to be paid upon clinical and regulatory milestone achievement | 165,000 | 165,000 | |||||
Maximum aggregate obligation to pay insignificant annual maintenance fees as well as clinical and regulatory milestone payments | $ 1,575 | ||||||
Notice period to terminate the agreement | 90 days | ||||||
Uncured period which causes termination of the agreement, due to insolvency or bankruptcy or for material breach of the agreement by the other party that remains uncured | 90 days | ||||||
Notice period to terminate the agreement under payment-related breaches | 30 days | ||||||
Research and development | $ 11 | $ 14 | $ 45 | $ 42 | |||
Asset Purchase Agreement | Biogen | Maximum | |||||||
License and Acquisition Agreements | |||||||
Milestone payment to be paid upon clinical and regulatory milestone achievement | $ 179,000 | ||||||
Milestone payment to be paid upon net sales milestone achievement | $ 150,000 |
In-license, Acquisition and C_3
In-license, Acquisition and Collaboration Agreements - Beth Israel Deaconess Medical Center License Agreement (Details) - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2022 | Sep. 30, 2021 | Sep. 30, 2022 | Sep. 30, 2021 | |
License and Acquisition Agreements | ||||
Research and development | $ 16,485 | $ 19,236 | $ 51,100 | $ 71,864 |
License Agreement | BIDMC | ||||
License and Acquisition Agreements | ||||
Research and development | 0 | $ 0 | 0 | $ 0 |
License Agreement | BIDMC | Maximum | ||||
License and Acquisition Agreements | ||||
Milestone payment to be paid upon clinical and regulatory milestone achievement | $ 1,200 | $ 1,200 |
In-license, Acquisition and C_4
In-license, Acquisition and Collaboration Agreements - Regeneron License Agreement (Details) - USD ($) $ in Thousands | 1 Months Ended | 3 Months Ended | 9 Months Ended | |||||
Feb. 28, 2022 | Sep. 30, 2017 | Sep. 30, 2022 | Sep. 30, 2021 | Mar. 31, 2021 | Sep. 30, 2022 | Sep. 30, 2021 | Dec. 31, 2021 | |
License and Acquisition Agreements | ||||||||
Research and development | $ 16,485 | $ 19,236 | $ 51,100 | $ 71,864 | ||||
Uncured period which causes termination of the agreement, due to insolvency or bankruptcy or for material breach of the agreement by the other party that remains uncured | 90 days | |||||||
Notice period to terminate the agreement under payment-related breaches | 30 days | |||||||
Consecutive suspension of activities period for termination of agreement | 12 months | |||||||
Notice period to terminate the agreement | 1 year | |||||||
Notice period to terminate the agreement if products are having safety concerns | 3 months | |||||||
Intangible asset - Regulatory milestone | 20,000 | 20,000 | $ 20,000 | |||||
Commercial product inventory | 14,621 | 14,621 | 3,675 | |||||
Regulatory milestone | ||||||||
License and Acquisition Agreements | ||||||||
Intangible asset - Regulatory milestone | 20,000 | 20,000 | 20,000 | |||||
Regeneron | License Agreement | ||||||||
License and Acquisition Agreements | ||||||||
Regulatory milestone payment | $ 20,000 | |||||||
Profit sharing recognized | 4,623 | 16,549 | $ 0 | |||||
Regeneron | License Agreement | Regulatory milestone | ||||||||
License and Acquisition Agreements | ||||||||
Intangible asset - Regulatory milestone | 20,000 | 20,000 | ||||||
Regeneron | License Agreement | Short-term liabilities | ||||||||
License and Acquisition Agreements | ||||||||
Profit sharing recognized | $ 6,000 | |||||||
Regeneron | Clinical Supply Agreement | ||||||||
License and Acquisition Agreements | ||||||||
Commercial product inventory | $ 14,621 | $ 14,621 | $ 3,675 |
In-license, Acquisition and C_5
In-license, Acquisition and Collaboration Agreements - MedImmune License Agreement (Details) - USD ($) $ in Thousands | 1 Months Ended | 3 Months Ended | 9 Months Ended | ||||
Jul. 31, 2020 | Sep. 30, 2017 | Sep. 30, 2022 | Sep. 30, 2021 | Sep. 30, 2022 | Sep. 30, 2021 | Dec. 31, 2017 | |
License and Acquisition Agreements | |||||||
Notice period to terminate the agreement by both parties for material breaches | 90 days | ||||||
Research and development | $ 16,485 | $ 19,236 | $ 51,100 | $ 71,864 | |||
MedImmune | License Agreement | |||||||
License and Acquisition Agreements | |||||||
Remaining milestone payments to be paid upon clinical and regulatory milestone achievement | 57,500 | 57,500 | |||||
Annual net sales excluded from calculation of specified annual net sales thresholds | $ 1,000,000 | ||||||
Maximum percentage of royalty payable on annual net sales of licensed products | 20% | ||||||
Notice period to terminate the agreement by both parties for material breaches | 90 days | ||||||
Notice period to terminate the agreement | 90 days | ||||||
Research and development | $ 0 | $ 0 | $ 0 | $ 0 | |||
Minimum | MedImmune | License Agreement | |||||||
License and Acquisition Agreements | |||||||
Additional specified annual net sales threshold for additional milestone payment. | $ 1,000,000 | ||||||
Maximum | MedImmune | License Agreement | |||||||
License and Acquisition Agreements | |||||||
Milestone payment to be paid upon specified milestone achievements for first two indications | $ 72,500 | ||||||
Milestone payment to be paid upon clinical and regulatory milestone achievement | $ 15,000 | ||||||
Milestone payment to be paid upon specified annual sales milestone achievements | 85,000 | ||||||
Additional specified annual net sales threshold for additional milestone payment. | $ 1,100,000 |
Earnings (Loss) per Share (Deta
Earnings (Loss) per Share (Details) - USD ($) $ / shares in Units, $ in Thousands | 3 Months Ended | 9 Months Ended | ||||||
Sep. 30, 2022 | Jun. 30, 2022 | Mar. 31, 2022 | Sep. 30, 2021 | Jun. 30, 2021 | Mar. 31, 2021 | Sep. 30, 2022 | Sep. 30, 2021 | |
Numerator: | ||||||||
Net income (loss) attributable to common shareholders | $ 224,093 | $ (19,981) | $ (25,210) | $ (30,544) | $ (41,563) | $ (49,484) | $ 178,902 | $ (121,591) |
Denominator: | ||||||||
Weighted-average basic shares outstanding | 69,445,071 | 68,662,673 | 69,305,755 | 68,444,061 | ||||
Effect of dilutive securities | ||||||||
Weighted-average diluted shares | 70,552,018 | 68,662,673 | 70,286,444 | 68,444,061 | ||||
Basic EPS | $ 3.23 | $ (0.44) | $ 2.58 | $ (1.78) | ||||
Diluted EPS | $ 3.18 | $ (0.44) | $ 2.55 | $ (1.78) | ||||
Options to purchase common shares | ||||||||
Effect of dilutive securities | ||||||||
Effect of dilutive securities | 937,492 | 906,866 | ||||||
Unvested RSUs | ||||||||
Effect of dilutive securities | ||||||||
Effect of dilutive securities | 169,455 | 73,823 |
Earnings (Loss) per Share - Ant
Earnings (Loss) per Share - Anti-Dilutive Securities (Details) - shares | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2022 | Sep. 30, 2021 | Sep. 30, 2022 | Sep. 30, 2021 | |
Anti-dilutive securities excluded from computation of earnings per share | ||||
Total, anti-dilutive securities excluded from computation of earnings per share | 9,310,394 | 10,357,635 | 10,427,438 | 10,357,635 |
Options to purchase common shares | ||||
Anti-dilutive securities excluded from computation of earnings per share | ||||
Total, anti-dilutive securities excluded from computation of earnings per share | 8,472,937 | 9,556,481 | 8,880,055 | 9,556,481 |
Unvested RSUs | ||||
Anti-dilutive securities excluded from computation of earnings per share | ||||
Total, anti-dilutive securities excluded from computation of earnings per share | 837,457 | 801,154 | 1,547,383 | 801,154 |
Income Taxes (Details)
Income Taxes (Details) - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | |||
Sep. 30, 2022 | Sep. 30, 2021 | Sep. 30, 2022 | Sep. 30, 2021 | Jul. 31, 2022 | |
Bermuda statutory income tax rate | 0% | ||||
Net operating loss carryforwards - Bermuda | $ 0 | $ 0 | $ 0 | $ 0 | |
Income tax benefit | 177,358 | $ 118 | 174,717 | $ (1,106) | |
Decrease in valuation allowance | 185,843 | ||||
Outside Kiniksa US and Kiniksa UK | |||||
Material deferred tax assets | $ 0 | $ 0 | |||
Kiniksa UK | |||||
Tax liabilities incurred | $ 0 |
Commitments and Contingencies (
Commitments and Contingencies (Details) $ in Thousands | Sep. 30, 2022 USD ($) |
Manufacturing commitments | |
Non-cancelable purchase commitments | $ 33,019 |